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Table 1. Parameters for Equation 4.1.4, which correlates the dimensionless 
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Although transdermal drug delivery provides patient convenience and sustained 
delivery in contrast to painful hypodermic injections, skin’s low permeability prevents 
passive delivery of most drugs. The development of microneedles that penetrate the skin 
barrier, but are small enough not to stimulate nerves, has the potential to deliver drugs 
across skin in a painless way. In previous studies, solid silicon microneedles have been 
shown to increase skin permeability for transdermal diffusion of a wide range of 
molecules. However, controlled injection by convective flow into skin using hollow 
microneedles has remained a challenge. To address this challenge, the goals of this study 
were (i) to provide experimental measurements coupled with numerical simulations to 
quantitatively describe fluid mechanics of flow within microneedles over a range of 
experimental conditions and needle geometries, (ii) to demonstrate and study the effects 
of diffusion-based delivery of insulin to diabetic rats in vivo using solid and hollow 
microneedles and (iii) to determine the effect of experimental parameters on 
microinfusion through hollow microneedles into skin to optimize drug delivery protocols 
and identify rate-limiting barriers to flow.      
We first studied fluid mechanics of flow through microneedles by carrying out 
experimental and theoretical studies. Experimentally, we quantified the relationship 
between pressure drop and flow rate through microneedles as a function of fluid viscosity 
and microneedle length, diameter, and cone half-angle. At small Reynolds number, 
dimensionless pressure drop decreased steeply with increasing Reynolds number, 
indicating the importance of viscous forces, and at large Reynolds number, dimensionless 
pressured drop was generally independent of Reynolds number, indicating that the flow 
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was almost inviscid. Microneedle tip diameter and taper angle were the primary 
controlling parameters for flow through conically tapered microneedles as shown by 
numerical simulations, which demonstrated good agreement with experimental data. A 
favorable axial pressure gradient that accelerates fluid through the microneedle, thus 
inhibiting growth of the viscous boundary layer on the microneedle wall, was shown as a 
characteristic feature of flow through conically tapered microneedles. Flow rates over a 
range of 1.4 – 56 µl/s were achieved through microneedles (in the absence of skin) with 
pressure drops in the range of 4.6 – 196.5 kPa. This study represents the first detailed 
study of fluid mechanics of flow in microneedles specifically and of developing flow in 
conical channels in general.  
This work also studied the use of solid microneedle arrays to insert into the skin of 
diabetic hairless rats in vivo for transdermal delivery of insulin. This study used arrays 
each containing 105 solid metal microneedles measuring 1000 μm long and 50 μm x 200 
μm in cross section. Blood glucose levels dropped by as much as 80% in diabetic hairless 
rats in vivo, indicating that solid metal microneedles were capable to increase transdermal 
insulin delivery. Reduction of blood glucose levels based on microneedle insulin delivery 
showed an extent similar to 0.05 – 0.5 U insulin injected subcutaneously. Direct 
measurement of plasma insulin concentrations were reported in the range of 0.5 – 7.4 
ng/ml. Larger drops in blood glucose level and larger plasma insulin concentrations were 
shown due to higher donor solution insulin concentration, shorter microneedles insertion 
time and fewer repeated insertions. This is the first study demonstrating delivery of a 
therapeutic protein, i.e., insulin using microneedles in vivo.  
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Transdermal insulin delivery in diabetic hairless rats in vivo was also shown using 
hollow microneedles, which were fabricated using a modified-LIGA and laser-trepanning 
process. Insulin delivery through an array of 16 hollow metal microneedles measuring 
500 μm in length with a 75 μm tip diameter were demonstrated to reduce blood glucose 
levels steadily to 47% of pre-treatment values over a 4-h insulin delivery period. Direct 
measurement of plasma insulin levels showed a peak value of 0.43 ng/ml. This study is 
the first demonstration of diffusion-based delivery through hollow microneedles.  
The final scope of this work was to determine the effect of microneedle geometry and 
infusion protocols on microinfusion flow rate into skin in vitro. Glass microneedles were 
fabricated using a micropipette puller and inserted to a depth of 720-1080 μm into human 
cadaver skin to microinfuse sulforhodamine. Infusion flow rates ranged from 21 to 1130 
µl/h was demonstrated using these microneedles. The presence of a bevel at the 
microneedle tip, larger retraction distance and insertion depth, larger infusion pressure 
and the presence of hyaluronidase led to larger infusion flow rates. Longer infusion time 
experiments suggest a constant flow rate after a short transient delay.  
In addition to demonstrating diffusion-based delivery in vivo using solid and hollow 
microneedles, this work provides an in depth study of convective delivery using hollow 
microneedles. By designing microneedles with an appropriate geometry and inserting 
needles and injecting fluid appropriately into the skin, hollow microneedles can be used 







Although sophisticated new drugs have been developed, their therapeutic delivery is 
often a challenge.  Drug could be transported into our body via different delivery routes: 
transdermal, nasal, oral, buccal, ocular, and pulmonary delivery (Langer 2001, Senel and 
Hincal 2001). Each of these routes offers some advantages and limitations. Oral delivery 
remains the most common way drugs are administered however many compounds are 
either degraded in the gastrointestinal tract or liver, or are poorly absorbed across the 
intestine. When this occurs, the usual alternative is to use a hypodermic needle for 
injection across the skin. Although hypodermic needle can effectively deliver large doses 
of drugs in a short time period, it has some limitations such as the pain associated with 
the injection, expertise required for injection and most importantly, difficulty for 
sustained delivery (Prausnitz 2001). 
Transdermal drug delivery from a patch is attractive as an alternative route because it 
eliminates the limitations associated with oral delivery and hypodermic needle injection 
(Prausnitz, Mitragotri, et al. 2004, Purdon, Azzi, et al. 2004). It offers good patient 
compliance and the possibility of controlled release over time, while avoiding possible 
degradation due to the gastrointestinal tract or first-pass liver effects (Bronaugh and 
Maibach 1999, Prausnitz, Mitragotri, et al. 2004). Adult human skin with large surface 
area offers a remarkable exposed area for transdermal drug delivery (Wille and 
Kydonieus 2000). The complex skin structure however remains the biggest challenge for 
researchers in the field. The outermost layer of skin (10 – 15 μm), stratum corneum, acts 
as a barrier to foreign materials and resists passive diffusion of most drugs across the skin 
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at a therapeutic rate. Thus the $2.8 billion worldwide transdermal patch market is only 
based on about a dozen drugs that share specific characteristics: low molecular mass, 
optimal physicochemical properties and effectiveness at low doses because of the high 
impermeability of human skin (Barry 2001, Prausnitz, Mitragotri, et al. 2004) . 
The idea to simultaneously capture the potential benefits of both hypodermic needles 
and transdermal patches led into the development of the micron-dimension needles 
concept, usually referred to as “microneedles” by delivering drug with high patient 
compliance (Henry, McAllister, et al. 1998). In previous studies, solid silicon 
microneedles have been shown to increase epidermis permeability for transdermal 
diffusion of a wide range of molecules (McAllister, Allen, et al. 2000). To extend 
microneedle capabilities to actively deliver drugs by convection, hollow tapered 
microneedles have also been fabricated (Davis 2003). However, fluid delivery into 
complex skin structure using microneedles remains a challenge. The effectiveness and 
potential application of microneedles as a device for fluid delivery into skin is the scope 
of this thesis. In addition, the use of both solid and hollow microneedles to deliver a 












2.1 Transdermal Drug Delivery 
Transdermal drug delivery is the transport of drugs across skin. Injection of drugs into the 
skin using a hypodermic needle remains the most common way to deliver drugs across 
skin. The conventional way of drug injection across skin has been performed by using 
hypodermic needles. This method of delivery proves to deliver drugs in large quantities 
in a controlled fashion. However, there are some drawbacks associated with this injection 
delivery method such as pain caused by the needle, lack of patient compliance, need for 
medical expertise to perform the injection, risk of infection and difficulty for sustained 
delivery. Transdermal drug delivery using patches, on the other hand, has the capability 
of eliminating these limitations associated with hypodermic needle injection such as lack 
of pain, infection, and sustained delivery (McAllister, Allen, et al. 2000, Mitragotri 
2000). The use of transdermal patches has been employed for the delivery of drugs that 
have optimal physicochemical properties which are compatible with stratum corneum 
such as clonidine, fentanyl, lidocaine, nicotine, nitroglycerin, oestradiol, oxybutinin, 
scopolamine and testosterone (Sifton 2003). Nevertheless, the rapid growth of 
transdermal drug delivery using patches has been limited by the types of drugs that can 
be delivered depending on their size, charge and other physicochemical properties (Naik, 
Kalia, et al. 2000). 
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2.1.1 Skin Anatomy 
Skin (Figure 2.1) can be divided into three regions: the outermost cellular layer called 
epidermis; the inner, relatively acellular layer called dermis; and the innermost layer 








Malphigian layer and the dead cells of the stratum corneum (Figure 2.1). Stratum 
corneum is a multilayered structure with thickness of approximately 10-20 μm that acts 
as an excellent chemical barrier of the skin. Keratin-rich corneocytes and multiple lipid 
bilayers (composed of ceramides, cholesterol, fatty acids, and cholesterol sulfates) form 
the ‘brick and mortar’ structure of the stratum corneum, respectively (Barry 2001). 
                                                 
1 reproduced from http://www.pg.com/science/skincare/Skin_tws_9.htm 
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The next layer below the stratum corneum is the viable epidermis layer (50 – 100 μm) 
that consists of keratinizing epithelial cells for the synthesis of the stratum corneum 
(Schaefer and Redelmeier 1996). This viable epidermis layer contains no vascular 
network and obtains its nutritional need by passive diffusion through interstitial fluid. 
The epidermis is connected to the 1 – 2 mm thick dermis layer by the epidermal-dermal 
junction. The dermis is an integrated fibroelastic, largely acellular structure that provides 
skin mechanical strength. This dermis layer contains extensive nerves and vascular 
networks.  
Despite the extensive research on transdermal drug delivery, natural skin property as 
an excellent barrier to foreign material remains as a challenge in this field. Many efforts 
in transdermal drug delivery research have been devoted to disrupting the hindrance 
provided by an intact stratum corneum. Drug enhancement by adjusting its partition 
coefficient, chemical potential, or by using a prodrug is one of the various ways to 
overcome the stratum corneum barrier (Barry 2001). Different types of chemical 
enhancers such as surfactants, fatty acids/esters, terpenes and solvents can increase skin 
permeability by various mechanisms, including enhancing solubility, increasing 
partitioning into the stratum corneum, fluidizing the stratum corneum crystalline structure 
and dissolving stratum corneum lipids (Finnin and Morgan 1999, French, Pouton, et al. 
1993, Kanikkannan, Kandimalla, et al. 2000, Williams and Barry 2004). Some other 
methods based on physical enhancement such as electroporation, iontophoresis and 
ultrasound were also found to successfully create pathways for drugs entering the skin 
(Barry 2001, Mitragotri, Coleman, et al. 2000, Prausnitz 1999). Electroporation involves 
the application of short, high-voltage pulses to transiently increase skin permeability 
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(Prausnitz, Bose, et al. 1993, Prausnitz 1999). Iontophoresis which uses an electric field 
to move both charged and uncharged species across the skin increases rates of 
transdermal transport by three different mechanisms: electrophoresis, electro-osmosis, 
and transiently increased skin permeability (Prausnitz, Mitragotri, et al. 2004). 
Ultrasound that involves cavitation and emission of acoustic microjets is considered to 
disrupt stratum corneum lipid bilayers (Mitragotri, Edwards, et al. 1995). However, low-
cost, simple, and reliable miniaturization of these latter delivery systems remains a 
challenge for home usage. Modification (by hydrating) and disruption of stratum 
corneum were also found to assist drug penetration into the skin (Marks, Barton, et al. 
1988). Disruption of the stratum corneum using gas-based high velocity projectiles and 
jet injectors has also been employed even though there is a main concern of bruising and 
sometimes bleeding that is difficult to avoid (Barry 2001, Bremseth and Pass 2001, 
Burkoth, Bellhouse, et al. 1999, Bykowski 1999). Thermal methods have also been used 
to increase skin permeability by locally heating and ablating holes in stratum corneum, a 
process called microporation (Bramson, Dayball, et al. 2003, Gebhart, Faupel, et al. 
2003).  
The ability to create a large enough transport pathway across stratum corneum for 
molecules to pass through however small enough for high patient compliance, thus 
eliminating the need of hypodermic needle, has led into the development of microneedles 
for transdermal drug delivery.  
2.2 Diabetes and Insulin Delivery  
Diabetes mellitus is one of the leading lethal diseases in the United States and 
worldwide, and is often treated by hypodermic injection of insulin. In the United States, 
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diabetes accounts for over 130 billion dollars of health care costs and is the fifth leading 
cause of death (Hogan, Dall, et al. 2003). Diabetes is classified by its underlying cause: 
type 1 diabetes, an autoimmune disease in which the body's own immune system attacks 
the pancreas, rendering it unable to produce insulin and type 2 diabetes that is caused by 
combination of insulin resistance with insulin deficiency (2003). These abnormalities 
lead to metabolism alterations of carbohydrates, lipids, ketones and amino acid as well as 
increased level of blood glucose (hyperglycemia). Hyperglycemia resulting from diabetes 
could eventually lead into further complications such as heart disease, blindness, kidney 
failure and pregnancy complications (Davidson 1998). 
Diabetes management involves tight control of blood glucose levels by keeping 
patient’s blood glucose levels as close as possible to normal levels. Glucose regulation 
within our body is controlled by the competing effects of two glucoregulatory hormones: 
insulin and glucagon. Insulin stimulates the glucose uptake and metabolism by muscle 
and adipose tissue and also inhibits the hepatic glucose production thereby reducing 
glucose concentration in blood. On the other hand, glucagon increases blood glucose by 
stimulating the conversion of glycogen (short-term energy reserve) into glucose. 
Subcutaneous insulin injection using hypodermic needle has remained the common way 
to administer insulin despite its limitations to restore normal glucose level in diabetic 
patients as well as discomfort associated with the pain and frequency of injection. The 
kinetics of injected insulin do not mimic the natural rise and fall of nutrient-related and 
basal insulin secretion.  
The need for daily multiple insulin doses and inconvenience associated with multiple 
needle injections has led into the development of insulin-infusion pumps. Available 
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insulin pumps in the market have some limitations including presently unavailable 
automatic glucose sensor feedback system, insulin aggregation in infusion line, pump 
failures and potential risk for subcutaneous cellulitis and abscesses (Goodman, Gilman, et 
al. 1996). There have been many efforts to develop alternative routes of delivery for 
insulin administration: peroral, buccal/sublingual, rectal, transdermal, intranasal, and 
pulmonary. Combined effects of the relatively thick multilayered buccal barrier and 
constant saliva flow limit the effectiveness of insulin delivery via mucosa of mouth 
(Aungst and Rogers 1988). High insulin doses and different strategies were employed to 
increase the permeability of intestinal mucosa such as enhancement of insulin stability, 
protection against proteolytic enzymes and use of surfactants (Shah, Ahsan, et al. 2002). 
Recently, there has been some success with oral insulin delivery system (Arbit 2004, 
Whitehead, Shen, et al. 2004). Rectally-injected insulin has limitations such as the need 
for enhancers (Chetty and Chien 1998, Matsuda and Arima 1999, Yun, Choi, et al. 1999) 
and its low bioavailability (Yamasaki, Shichiri, et al. 1981). The use of iontophoresis 
(Langkjaer, Brange, et al. 1998), low-frequency ultrasound (Mitragotri, Blankschtein, et 
al. 1995), and transfersomes (Cevc 2004) to increase skin permeability of large 
hydrophilic polypeptides such as insulin has had limited success. However transdermal 
route still remains as an attractive route for insulin delivery. Nasally-administered insulin 
with similar pharmacokinetic profile of intravenous insulin has some drawbacks 
including its low bioavailability (Drejer, Vaag, et al. 1992, Hinchcliffe and Illum 1999), 
short duration action (Bruce, Chisholm, et al. 1991, Hilsted, Madsbad, et al. 1995) and 
variable absorptions (Gizurarson and Bechgaard 1991).  Large surface area, highly 
permeable epithelium (Weibel 1964, Weiss, Berger, et al. 1999, Weiss, Cheng, et al. 
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2003), and lung immunotolerance (Patton and Platz 1992) are advantageous for 
pulmonary insulin delivery. Despite low bioavailability (Patton, Bukar, et al. 2004, Rave, 
Nosek, et al. 2004) and the possibility of pulmonary hypotension and oedema due to high 
insulin concentration (Weiss, Berger, et al. 1999), recently, there has been significant and 
promising progress of inhaled insulin delivery system (Hollander, Blonde, et al. 2004, 
Quattrin, Belanger, et al. 2004, Rave, Nosek, et al. 2004, Rosenstock, Cappelleri, et al. 
2004). 
Given the large surface area of skin available for transdermal drug delivery, thus 
arrays of microneedles have the potential to provide transport pathways for insulin 
delivery into skin. These needles can pierce the skin and create micron-scale openings, in 
the case of solid microneedles, or provide a conduit for insulin transport across the skin in 
the case of hollow microneedles. While still extremely small on a clinical level, channels 
of microns dimensions are much larger than macromolecules and thereby should 
dramatically increase skin permeability to large drug molecules such as insulin. Given the 
very low diffusivity of many drug molecules, including insulin, in stratum corneum, 
microneedles can also increase drug molecules diffusivity across the skin. Microneedles 
also eliminate the pain associated with multiple hypodermic needle injection of insulin 
and offer the potential for controlled and automated insulin delivery, i.e., integrated with 
micropumps and glucose microsensors. 
2.3 Microfabrication  
Desired microneedle properties such as small dimension, sharpness and strength to 
insert into skin in a painless fashion suggests the use of microfabrication as a primary 
method to make these microneedles. Microfabrication, i.e., micro-machining or micro-
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electromechanical systems (MEMS), is a rapidly growing field that applies tools 
developed in microelectronics field to create mechanical or electrical devices. 
Fundamentally, microfabrication involves material deposition (additive), material etching 
(subtractive) and patterning processes (Madou 2002).   
The potential application of MEMS for the development of microfeatures in 
biomedical field led into the birth of BioMEMS. Drug delivery, DNA sequencing devices 
(Katsuma and Tsujimoto 2001), biosensors and chemical analysis systems (Lindner 
2001) are few among many other applications that benefit from the advances in 
BioMEMS technology. The compelling factor to fabricate devices with the same size as 
the biological entity of interest has led into the development of wide variety of 
biologically-relevant micron size devices such as micro-total-analysis system (μ-TAS) 
(Wang, Lu, et al. 2000), microreservoir for drug delivery (Ahmed, Bonner, et al. 2002) 
and silicon immunoisolating biocapsules (Leoni and Desai 2004).  
2.3.1 Laser Micromachining 
Laser micromachining that involves material ablation offers high quality three- 
dimensional features fabrication in a single step and dry process (Harvey, Rumsby, et al. 
1995, Rizvi, Rumsby, et al. 1999). The use of laser micromachining has emerged from its 
application in microvias drilling in chip interconnection packages in early 1980s  to being 
a key player nowadays in the development of micro structures in MEMS (Gower 2000) 
for diverse industrial applications including ink jet printer nozzles (Dyer 2003), arterial 
blood gases sensors (Gower 1999), lab-on-chips components (Pugmire, Waddell, et al. 
2002), and micro diffractive lenses (Lippert, David, et al. 2001).  
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2.3.2 Polymer and Micromolding Process 
The development of SU-8, an epoxy-derivative of bis-phenol-A novolak has 
benefited the MEMS field, especially in the area of photolithography in which 
previously, low resolution, low aspect ratio and high optical absorbency were among the 
disadvantageous characteristics of photoresist materials. SU-8’s unique properties such as 
low optical absorption in the UV range, good adhesion properties and low cost have led 
its use in the fabrication of high aspect ratio, three dimensional MEMS structures 
(Bertsch, Lorenz, et al. 1999).  
The use of polydimethylsiloxane (PDMS) in micromolding process has been widely 
used to replicate microstructures (Xia and Whitesides 1998) due to its low cost, 
durability, and transparency. Polymers in general and biodegradable and biocompatible 
polymers in specific have been extensively studied and used in both MEMS and drug 
delivery areas. Despite the large number of available degradable polymers, there is only a 
handful of these polymers which are considered safe for internal human use such as poly 
(lactic-acid) / PLA, poly (glycolic-acid) / PGA and their copolymers (Ratner 2004). 
2.4 Evolution of Microneedles 
The idea of combining the benefits of needle injection and transdermal patches while 
eliminating the drawbacks associated with each technique resulted in the creation of the 
microneedles concept. This concept involves micron-size needles, generally hundreds of 
microns long, ones to tens of microns wide at the tip, and on the order of 100 μm wide at 
the base. These needles are sufficiently long to penetrate skin’s outer permeability 
barrier, deep enough to allow capillaries uptake but short enough to avoid nerve endings 
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(Henry, McAllister, et al. 1998, McAllister, Allen, et al. 2000). The idea behind the 
development of microneedles is to pierce into skin and to create molecular or liquid 
transport pathways across the skin. Microneedles have evolved from their simplest form 
of solid spikes to hollow microneedles that could be integrated with micropumps or other 
microfeatures with different functionality. 
2.4.1 Solid Microneedles 
Early design microneedles were in the form of solid microneedles. These 
microneedles have been designed and used to create micron-size openings in the skin and 
thus allow molecular transport into skin. Solid microneedles tend to be sharp and simpler 
to fabricate compared to hollow microneedles.    
2.4.1.1 Silicon Microprobes 
One of the earliest solid microneedle design was in the form of pyramidal silicon 
microprobes, shown in Figure 2.2 (Hashmi, Ling, et al. 1995). The fabrication step 
involves spin-casting a photoresist (photosensitive polymer) onto a silicon-dioxide coated 
wafer, bringing the wafer into contact with a photomask (glass plate with chromium 
pattern on it) and exposing it to UV light. The exposed photoresist portions (not covered 
by chromium pattern) are eventually removed during the development step. The 
transferred pattern (from photomask to photoresist) is then etched into the silicon dioxide 
masking layer. Subsequently, the photoresist is removed and the wafer is anisotropically 
wet-etched in potassium hydroxide solution to create arrays of pyramidal probes. These 
micropobes are ten to several hundred microns in height and are extremely sharp (tip 
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Figure 2.2 Solid silicon microprobes used to deliver genes to plant, nematodes and 
mammalian cells (Hashmi, Ling, et al. 1995). 
 
 
2.4.1.2 Silicon Microneedles 
The use of solid microneedles for transdermal drug delivery was first demonstrated 
soon after the development of the silicon microprobes (Henry, McAllister, et al. 1998). 
These solid microneedles were fabricated using deep reactive ion etching method. The 
fabrication steps include depositing a chromium masking layer onto a silicon wafer, 
patterning it using photolithography into dots with the size of the desired needle base. 
The wafer is then etched by an oxygen/fluorine plasma mixture in a reactive ion etcher to 
create high aspect ratio solid silicon microneedles. These needles measure approximately 
80 μm at the base, 150 μm tall, and approximately 1 μm radius of curvature at the tip and 
shown in Figure 2.3. These needles were capable to insert into skin without breaking and 
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increase the permeability of human epidermis to calcein (623 Da; r = 0.6 nm), insulin 
(hexameric form: 35 kDa; 2.5 nm), and bovine serum albumin / BSA (66 kDa; 3.5 nm) in 




Figure 2.3 Solid silicon microneedles used for transdermal delivery and capable to increase 
human epidermis permeability to calcein, insulin and bovine serum albumin (Henry, 




Another type of solid silicon microneedles called microenhancer arrays (MEA) was 
fabricated using lithography and isotropic potassium hydroxide etch techniques and 
shown to deliver naked plasmid DNA into mice skin. The needle arrays were placed in 
contact with DNA solution and scraped multiple times across the skin thus creating 
microabrasion effects and increase in reporter gene activity up to 2,800-fold above 
topical controls. These needles measure 50 – 200 μm in length and have blunt tip, shown 




Figure 2.4 Microenhancer (MEA) array for skin microabrasion during naked plasmid DNA 
delivery into mice skin (Mikszta, Alarcon, et al. 2002). 
 
 
2.4.1.3 Polymer Microneedles 
High material and fabrication costs associated with the fabrication of silicon 
microneedles have led into the use of other materials for microneedles fabrication. 
Polymer microneedles offer several benefits such as ease of manufacture, higher safety 
efficacy and ability to act as drug carrier (in the case of implanted biodegradable 
polymer).   Different types of polymer have been used as basic materials to fabricate 
microneedles. 
2.4.1.3.1 Beveled Microneedles 
Beveled needles exert asymmetric forces into tissue thus allows easier penetration 
into skin. Beveled polymer microneedles made of biodegradable polymer, poly (glycolic 
acid) / PGA were fabricated using combinations of photolithography, metal coating for 
masking, reactive ion etching and micromolding techniques (Park 2004). The fabrication 
steps include coating SU-8 photoresist onto a silicon wafer, lithographically patterning 
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into cylinders, filling the space between the cylinders with a sacrificial polymer, 
depositing copper masking layer, partially removing the sacrificial layer and 
asymmetrically etching the tip of the cylinders. After removing the remaining sacrificial 
layer, it leaves behind an array of beveled SU-8 microneedles.  In order to make the final 
PGA needles, the next step is to replicate these SU-8 needles by coating 
polydimethylsiloxane onto the needles to make an inverse mold, filling this mold with 
PGA polymer powder and melting it under vacuum.  
With 600 μm in height, 100 μm at their bases, and 10 μm at their tips, these PGA 
needles are positioned in a 20 by 6 array with a center-to-center spacing of 400 μm and 
1400 μm (shown in Figure 2.4). Similar needles made of other biodegradable polymer, 
poly (lactide-co-glycolide) / PLGA were loaded with calcein and BSA and shown to 
insert into skin without breaking. The release pattern and rate of calcein and BSA in 
phosphate buffered saline solution (PBS) were shown to be different. The release pattern 
of calcein depended on calcein bulk diffusion rather than slower polymer degradation, on 
the other hand, the release pattern of BSA depended on slower BSA diffusion and 
polymer needle surface erosion (Park, Davis, et al. 2003). In addition, these needles were 




Figure 2.5  Beveled solid biodegradable polymer microneedles (Park 2004).  
 
 
2.4.1.3.2 Beveled Microneedles with Notch 
Following similar fabrication steps as beveled microneedles (shown above), an array 
of beveled microneedles with notch can be fabricated by using a mask that has a notch. 
The notch dimension is controlled by the notch size and geometry in the circular 
patterned mask. These needles have similar dimensions to those without the notch and are 







Figure 2.6 Beveled solid polymer microneedles with notch (Park 2004). 
 
 
2.4.1.3.3 Tapered Polymer Microneedles 
Tapered polymer microneedles were fabricated using unconventional exposure 
patterns in SU-8 through integrated microlenses. These lenses were fabricated on a glass 
substrate by chromium-masked isotropic wet etching. SU-8 was subsequently coated onto 
the substrate and exposed from the backside. The sharp tapered structures resulted from 
both the aligned beam through the microlenses and light-blocking effect of the chromium 
on the non-lens portions of the substrate. An array of 200 PGA microneedles (Figure 2.6) 
with base diameter of 200 μm, tip diameter of 20 μm and height of 1.5 mm was 
fabricated after replicating SU-8 master structures using PDMS micromolding technique 




Figure 2.7 Tapered solid polymer microneedles fabricated using lens technique (Park, 
Yoon, et al. 2004). 
 
 
2.4.1.4 Metal Microneedles 
Metal is considered to be another candidate for microneedles because it offers added 
mechanical strength, ease of fabrication, relatively inexpensive cost and established 
safety records in medical applications.  
Different styles of solid metal microneedles have been developed for transdermal 
drug delivery. Microprojection titanium arrays (Macroflux®) are fabricated by applying a 
thin layer of photoresist onto a titanium or stainless steel sheet, contact-exposing and 
developing the resist with the desired pattern and bending the arrays to a 90º angle 
(relative to the horizontal plane). These microprojections (alone or in combination with 
iontophoresis) which measure 175-430 μm in length and arranged in an array with 
density of 190-320 microprojections/cm2 were shown to deliver oligodeoxynucleotides 
and human growth hormone across hairless guinea pigs skin (Cormier and Daddona 
2003, Lin, Cormier, et al. 2001).  
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These Macroflux® microprojection arrays were also shown to administer synthetic 
peptide transdermally to hairless guinea pigs skin by coating the arrays with 
desmopressin (Cormier and Daddona 2003, Cormier, Johnson, et al. 2004). A related 
study showed the use of these microneedles to deliver ovalbumin, a model protein 
antigen coated on the needle surface. Antibody responses were shown to give up to 50-
fold greater immune response compared to that of subcutaneous or intramuscular 
injection dose (Matriano, Cormier, et al. 2002).  Similar needles, have also been used to 
deliver synthetic parathyroid gland hormone in human subjects and demonstrated to have 
faster absorption rate than that of injectable hormone using subcutaneous injection 




Figure 2.8 Metal microprojection arrays etched from a titanium sheet shown used to deliver 
(left) protein antigen in animal (Matriano, Cormier, et al. 2002) and (right) synthetic 





2.4.2 Hollow Microneedles 
Skin permeability can be dramatically increased by the holes created from solid 
microneedle insertion or abrasion. However, it is necessary to have more controlled and 
reproducible transport pathways to deliver drugs into the skin. The fabrication of hollow 
microneedles that allows drug transport through the bore of the needle was based on this 
need. Hollow microneedles allow the increase of fluid pathway into the skin through the 
bore of the needle and offer the potential for larger molecules to be delivered into skin in 
a controlled fashion. Solid microneedles diffusion-based delivery could be expanded to 
convective delivery using hollow microneedles, i.e., by pressure-driven flow or by 
incorporating syringe pump with microneedle arrays.   
2.4.2.1 Silicon Microtubes 
The inclusion of a lumen in solid silicon microneedles seems to be a logical step 
during the early design of hollow microneedles. Hollow silicon microtubes were 
fabricated by first defining the lumen by etching through silicon wafer thickness using 
deep reactive ion etching (DRIE) technique in an inductively coupled plasma reactive ion 
etcher (ICP-RIE) (McAllister 2000). This DRIE process involves a deposition step in 
which all surfaces including the trench sidewalls are coated with a teflon-like protective 
layer, etching step in which protective layer is selectively removed from the trench floors 
by high ion bombardment and a subsequent etch step to remove the silicon. Thus, it 
allows a deep and anisotropic etching process. After the lumen is defined, a concentric 
hole surrounding the lumen must be etched to create hollow microtubes using ICP-RIE 









The microtubes measure 150 μm in height, with 80 μm outer diameter, 40 μm inner 
diameter and 300 μm center-to-center spacing.  
2.4.2.2 Silicon Microneedles 
Arrays of hollow silicon microneedles (as further refinement of hollow tubes 
presented above) were fabricated using standard photolithography and isotropic- 
anisotropic etching combination (Stoeber and Liepmann 2000). The fabrications steps 
started with silicon dioxide coating on a silicon wafer, patterning the backside of the 
wafer with circular mask and etching all the way through the wafer stopping on the upper 
oxide layer to define the needle lumen. Silicon nitride was then deposited to act as etch 
stop within the lumen. A larger circular mask was patterned on the frontside and then 
underetched to create the tapering effect of the needle. Both silicon dioxide and silicon 
nitride layers were then removed. Symmetrical and asymmetrical (tapered) needle 
 23
structured can be achieved by adjusting the relative position of the isotropic and 
anisotropic etching axis. The needles, shown in Figure 2.10, were arranged in up to 8 
needles per array with 40 μm lumen diameter and 200 μm in height. In vitro insertion of 





Figure 2.10 Hollow silicon microneedles fabricated using lithography and etching 




A similar study with slight modification in the fabrication process allows the 
flexibility of positioning the lumen opening with respect to needle tip. The fabrication 
involves simultaneous reactive ion etching of a hole that defines the lumen and a slot that 
defines the needle tip position (Gardeniers, Berenschot, et al. 2002, Gardeniers, Luttge, et 
al. 2003). A connecting hole was then etched from the other side of the wafer and a 
protective layer of silicon nitride was then deposited everywhere including the inner side 
of the lumen and the slot. Subsequently, after removing the silicon nitride on the upper 
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layer, wet-etching in basic solution creates taper structure bound by slow-etching {111} 
silicon plane. The protective layer was then removed to leave hollow beveled silicon 
needle structures (shown in Figure 2.11) which measure 400 μm tall, 70 μm hole 
opening, 250 μm base and approximately 40 μm center hole distance from the needle tip. 





Figure 2.11 Hollow beveled silicon microneedles used to withdraw blood by capillary action 
in human skin (Gardeniers, Berenschot, et al. 2002, Gardeniers, Luttge, et al. 2003). 
 
 
2.4.2.3 Polymer Microneedles 
Hollow polymer microneedles were fabricated using the combination of conventional 
LIGA (lithography, electroplating and molding) and inclined hard x-ray exposure (Moon, 
Sang-Jun, et al. 2003). The first step involved the mask fabrication for hard x-ray 
patterning. The x-ray exposure composed of two steps: standard vertical exposure that 
defined the needle base and vertical structure and inclined x-ray exposure that created the 
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sharp needle tip.  These PMMA (polymethylmethacrylate) needles are 470 μm in base, 
900 μm in height, has 20° side-wall angle, 750 μm center-to-center spacing and arranged 
in an 120 needles/cm2 density array. These needles, shown in Figure 2.12, were reported 




Figure 2.12 Hollow polymer microneedles fabricated using inclined x-ray exposure used to 
extract blood in human skin (Moon, Sang-Jun, et al. 2003). 
 
 
2.4.2.4 Metal Microtubes 
Hollow metal microtubes were fabricated either by photolithographically defining 
holes in SU-8 or by using silicon micromolds consisting of cylindrical holes created by 
DRIE through silicon wafers (McAllister 2000). The first method consisted of few 
different steps including depositing a thin titanium adhesion layer onto a substrate 
(silicon wafer or glass slide) before coating the substrate with SU-8. The SU-8 was then 
lithographically patterned into arrays of circular holes and eventually separated from the 
substrate by removing the titanium layer to yield SU-8 molds of cylindrical holes. 
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Subsequently, these molds were electroplated to create hollow metal microtubes. The 
second method on the other hand, involved creating the silicon micromolds by etching 
the entire thickness of silicon wafers using DRIE, a similar process to etch the lumens of 
hollow silicon microtubes, and then electroplating these molds to create hollow metal 
microtubes (shown in Figure 2.13). These microtubes are 200 μm in height, 80 μm in 
outer diameter and have 6 μm wall thickness with 150 μm center-to-center spacing. It 
was reported that the insertion of these microtubes into human cadaver skin was difficult. 
The microtubes tend to act as micro-punches in which they were clogged with epidermis 




Figure 2.13 Hollow metal microtubes fabricated using photolithography or deep reactive 
ion etching (McAllister 2000).  
 
 
2.4.2.5 Metal Microneedles 
Hollow metal microneedles were originally created in the two-dimensional in-plane 
style. Multiple-needle design (Brazzle, Papautsky, et al. 1998) and its modified design, 
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single-needle design with multiple output ports (Brazzle, Mohanty, et al. 1999), were 
both fabricated in similar fashion. The underside of the needles was formed by selectively 
electroplating palladium onto a silicon wafer. The inner dimension of the needles was 
defined by patterning a thick photoresist sacrificial layer. The sidewalls and top surfaces 
of the needles were defined by first coating a seed layer onto the photoresist continued by 
the electroplating of palladium onto this seed layer. To yield the final needle structures, 
the photoresist and the underlying seed layer were then removed. The multiple-needle 
design had 20 μm by 40 μm microchannels with 20 μm wall thickness and arranged in a 
25-needle linear arrays with 200 μm center-to-center spacing. These needles were 
proposed both as microhypodermic needles and for use in sustained transdermal drug 
delivery, although not shown. The single-design with multiple ports had 140 μm by 20 
μm channel size, shaft dimensions of 200 μm by 60 μm, tip dimensions of less than 15 
μm by 15 μm, a distance of 300 μm from tip to first outlet port and was 6 mm in length 






Figure 2.14 In-plane hollow metal microneedle: (left) multiple needle design (Brazzle, 
Papautsky, et al. 1998) and (right) single needle design with multiple ports (Brazzle, 




Early design of out-of-plane hollow metal microneedles were made from SU-8 molds 
that were based on solid silicon microneedles (McAllister 2000). Thin SU-8 layer was 
spin-coated onto an array of solid microneedles and then cross-linked by exposing it to 
UV light. The next step was to expose the needle tips by plasma etching some of the SU-
8 using RIE. The samples were then flipped over and all the silicon was etched. This 
resulted in an SU-8 mold with conical holes bored completely through it that can be used 
to fabricate hollow metal microneedles with similar features to the solid silicon master 
structures. A seed layer composed of titanium/copper/titanium (Ti/Cu/Ti) was sputter 
deposited onto the mold to provide uniform and highly conductive surface to electroplate 
metal onto. The upper titanium layer serves to protect the copper from oxidizing, the 
copper layer provides the conductive surface and the lower titanium layer promotes better 
adhesion to the silicon surface. After being electroplated, the metal needles were released 
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by breaking away the SU-8 mold with tweezers. Hollow metal (nickel-iron) microneedles 
resulted from this process were arranged in a 20 by 20 array, 80 μm at their bases, taper 
to 10 μm at the tips, 150 μm in height, with 3 μm wall thickness and 150 μm center-to-
center spacing. The needle bores are conical with decreasing diameter from the base (~ 
145 μm) to the tip (~ 5 μm). These needles (shown in Figure 2.15) were strong enough to 




Figure 2.15 Hollow metal microneedles fabricated using combination of lithography, 
reactive ion etching and electroplating and shown to repeatedly insert and removed from 




An alternative way to fabricate tapered hollow metal microneedles was demonstrated 
by laser-drilling tapered holes into polymer substrate, electroplate the polymer mold and 
wet-etching the mold to reveal the final needle structure (Davis 2003). Tapered structure 
decreases insertion force by reducing the interfacial area of the needle that is in contact 
with the skin. The energy distribution of the laser inherently creates a tapering effect 
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during the drilling of the polymer substrate. A Ti/Cu/Ti seed layer was then sputter-
deposited onto the mold prior to nickel electroplating. The sacrificial mold was then 
removed by wet-etching process in basic (KOH or NaOH) solution to yield tapered 
hollow metal microneedles (shown in Figure 2.16). For many applications, multi-needle 
microneedle arrays are especially interesting, because they can deliver more drug and 
provide redundancy not offered by single needles. Figure 2.16 shows an array of 
microneedles each with a height of 500 μm, base diameter of 300 μm, tip diameter of 75 
μm, and wall thickness of 10 μm arranged in a 4 x 4 (i.e., 16-needle) array with 600-μm 
needle-to-needle spacing.  As shown in the image, the height of each microneedle is 




Figure 2.16 Array of tapered hollow metal microneedles shown next to the tip of  a 27 gauge 





2.4.3 Integrated Microneedle Devices 
Advancements in microfabrication field, especially in MEMS led into the possibility 
of creating an integrated device in which additional functionality such as sensing or 
pumping unit is incorporated with microneedles. Biopotential electrodes that consists of 
silver-silver chloride (Ag/AgCl)-coated silicon microneedle arrays (2 mm by 2 mm) were 
fabricated using deep reactive ion etching process (Griss, Enoksson, et al. 2001). These 
needle electrodes demonstrated low electrode-skin-electrode impedance thus allowing 









Another type of integrated microneedle device was fabricated by adding a sensing 
unit to an in-plane needle. A similar in-plane single-needle design with multiple outlet 
ports (Brazzle, Mohanty, et al. 1999) described above was incorporated with a 
bioluminescence biosensor located in inner side of the needles (Brazzle, Bartholomeusz, 
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et al. 2000). Bioluminescence that reflects metabolic reaction is based on the light change 
intensity that is stoichiometrically related to time-dependent adenosine triphosphate 
(ATP) change (Chandrasekaran and Frazier 2002, Chandrasekaran, Mohanty, et al. 
2003).  
There are few other examples of integrated microneedle devices. Hollow silicon 
microneedles (Stoeber and Liepmann 2000) described above were incorporated with blue 
and polystyrene fluorescent beads-contained PDMS reservoir on the backside of the 
needles. These needles were inserted into chicken breast to demonstrate the delivery of 
the beads into different target depths. The deflection of the PDMS reservoir driven by 
thumb push allowed the fluid to flow (Stoeber and Liepmann 2002). A further extension 
for the use of these hollow silicon microneedles was demonstrated in a minimally-
invasive self-calibrating glucose monitoring system (Zimmermann, Fienbork, et al. 
2003). Once the needle was filled with interstitial fluid (ISF), glucose diffused through 
the integrated porous dialysis membrane into dialysis fluid and this fluid pumped past an 
















Figure 2.18 Prototype of microneedle-based glucose sensor which incorporates array of 8 
hollow 200-μm tall silicon microneedles with glucose sensor located in the Pyrex® flow 




Another type of hollow silicon microneedles integrated with microfluidic channels 
(shown in Figure 2.19) was used in transdermal ISF extraction (Mukerjee, Collins, et al. 
2004, Mukerjee, Isseroff, et al. 2003). The needles were fabricated using the combination 
of wet and dry etching, wafer sawing and anodic bonding to glass. The needles were 15 
μm2 in tip opening, 250 μm tall, with center-to-center spacing of 300 μm. The 
microchannels were also made using DRIE technique with 80 μm in width. Insertion into 








Figure 2.19 Front and backside of microneedle array used for interstitial fluid extraction 




Complex integrated microneedles with MEMS micropump device has also been 
demonstrated to provide continuous pumping up to 6 hours without failing (Zahn, 
Deshmukh, et al. 2001). The pumping mechanism was based on the expansion of a 
bubble generated by resistive heaters and the collapse of the bubble. The needles were in-
plane hollow silicon microneedles fabricated using polysilicon molding process (Zahn, 
Trebotich, et al. 2000). Further integration of this micropump device with microvalves 
and electrochemical sensor was shown capable of sampling and analyzing biological 
solutions (Zahn, Deshmukh, et al. 2001) when combined with array of microdialysis 
microneedles (shown in Figure 2.20). These needles selectively separate large molecular 





Figure 2.20 Integrated microfluidic device consists of micropump, microdialysis 
microneedles, microvalves and glucose sensor (Zahn, Deshmukh, et al. 2001). 
 
 
2.5 Fluid Flow through Microneedles 
Understanding the fluid dynamics of microneedles is important because microneedles 
can be used to flow drug solutions into skin or flow other fluids for other microfluidic 
applications. Hollow microneedles can increase drug transport by allowing fluid flow 
through their lumens. The pressure drop required to flow fluid through a microneedle 
depends on needle geometry and fluid viscosity and density. Needles of micron 
dimensions can exhibit significant resistance to flow. In the context of transdermal drug 
delivery applications, measurement and prediction of microneedle fluid dynamics is 
needed to design needles that balance between geometries small enough to avoid pain, 
sharp enough to easily insert into skin, and large enough to permit useful flow rates at 
reasonable pressures. A preliminary study of fluid flow using hollow microneedles 
showed that a large flow rate of water (10 – 50 ml/min) can be flowed through an array of 
100 hollow silicon microneedles at modest pressure (0.8 – 3.2 psi) (McAllister 2000). 
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Hollow metal microtubes mounted on standard 1 ml syringes have also been used to 
lower the blood glucose level in diabetic rats in vivo by the injection of insulin (data not 
shown) (McAllister 2000).  
Nevertheless, there have been some limitations of using microneedles for flowing 
fluids through into skin. Needle clogging with tissue, fluid leaking back out of skin 
through parallel pathways along the outer needle shaft, and fluid blocking due to rigid 
microstructure of skin were observed. Needle clogging caused by tissue pieces prevented 
fluid passage into skin. Fluid leaking during injection causes ineffective injection. Fluid 
passage and absorption can also be prevented because of rigid microstructure of skin. 
There has been a growing interest in characteristic studies of fluid flow inside small 
microchannels in general (Gad-el-Hak 1999, Mala and Li 1999, Papautsky, Brazzle, et al. 
1998, Stone and Kim 2001) as well as inside microneedles (Brazzle, Papautsky, et al. 
1998, Chandrasekaran and Frazier 2003, Griss and Stemme 2003, Stoeber and Liepmann 
2000) . However, none of these studies considered fluid flow through a conical structure 
channel. The study of fluid flow through conical macro-scale channels has been of 
interest for a century. Approximate analytical solutions have been derived with the 
assumption of creeping flow, limited contraction factor, and small taper angle (Kwon, 
Shen, et al. 1986, Oka 1964, Sutterby 1964). Despite some experimental study 
(Kemblowski and Kiljanski 1975) and extensive numerical analysis study of fluids in 
macro-scale conical channels (Garrioch and James 1997, Jarzebski and Wilkinson 1981), 
there has been no experimental study associated with fluids in a micro-scale conical 
structure. In addition to that, the experimental study of fluid flow through conical 
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channels at a high Reynolds number in which inertial effect dominates viscous effect is 


























3.1 Fluid Dynamics of Microneedles2 
3.1.1 Experimental Methods 
To quantify the relationship between applied pressure drop and flow rate as a function 
of microneedle geometry, polyester films (Mylar, DuPont Teijin Films, Wilmington, DE) 
were drilled using a 248-nm wavelength UV Excimer Laser (ATLEX 300i, Resonetics 
Micromaster, Nashua, NH) operated at 200 Hz and an energy density of 2.0 J/cm2 to 
create microneedle molds of defined length Ln, inlet diameter Di, tip diameter Dt, and 
cone half-angle θc. Mylar was chosen as material of interest for the mold because of its 
relatively low cost and ease of removal during processing. The molds were then cleaned 
by wiping the surface with methanol (Sigma Aldrich, St. Louis, MO) to remove residual 
surface contamination from the laser drilling process. Mold dimensions were determined 
using a digital stereomicroscope (Quadra Chek 200, Metronics Incorporated, Bedford, 
NH). To account for imperfections in geometry, effective needle tip diameter was 
calculated based on the area of the needle bore at the tip, assuming a circular geometry 
(LSM 510 Image Browser, Zeiss, Germany). The creation of a conical structure with a 
bigger entrance than its exit is made possible by tracing a pattern with the beam that will 
have a greater fluence, or energy density, at the center of the circle than that at the 
                                                 
2 This work was carried out in collaboration with Prof. Marc Smith and was published in Martanto, W., 
Smith, M. K., Baisch, S. M., Costner, E. A. and Prausnitz, M. R. Fluid dynamics in conically tapered 
microneedles. AIChE J 51: 1599-1607 (2005). 
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exterior (Davis, Martanto, et al. 2005). Scanning electron micrographs of hollow 




Figure 3.1 Scanning electron micrographs of hollow microneedles. (A) An array of 
microneedles is shown next to the tip of a 30-gauge hypodermic needle. (B) A single 
microneedle is shown from a side view. (C) The polymer mold used to make that needle is 
shown from above. Needle and mold dimensions are Ln = 500 μm, Di = 220 μm, Dt = 56 μm, 




To simplify the experimental protocol, fluid flow measurements were not made on 
microneedles, but were made on the molds used to fabricate microneedles. Although 
details of surface properties and orifice geometries differ between polymer molds and 
metal needles, we expect that molds and needles having the same internal geometry will 
still produce similar flow fields when given the same pressure drop.   
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The fluids used in this study were filtered deionized water, glycerin solutions, and 
bovine calf blood (in Alsevers anticoagulant, Rockland Immunochemicals, Gilbertsville, 
PA). The pressure drop measurement for deionized water was performed at room 
temperature (~22°C). Because the viscosity of glycerin solutions and blood is sensitive to 
temperature, studies with these fluids were performed in controlled-temperature rooms 
(4°C for glycerin solutions and 37°C for blood to model body temperature). Glycerin 
solutions were prepared by mixing filtered deionized water with glycerin (Fisher 
Scientific, Suwanee, GA) to yield 0, 7, 36, and 48 wt% glycerin solutions.  
The viscosity (Cannon Ubbelohde Viscometer, Cannon Instrument, State College, 
PA) and density (BP 210S digital balance, Sartorius, Goettingen, Germany) of the 
glycerin solutions with increasing glycerin content were determined at 4°C to be 1.0, 2.1, 
5.1, and 9.8 mPa·s and 1.00, 1.00, 1.06, and 1.12 × 103 kg/m3, respectively. Viscosity and 
density of deionized water at 22°C was 1.0 mPa·s and 998 kg/m3, respectively, and blood 
at 37°C was 1.7 mPa·s and 1.04 × 103 kg/m3, respectively. Although blood exhibits non-
Newtonian behavior, comparison with previous measurements suggests that this viscosity 
value is representative over the range of shear rates encountered in this study (Sushil, 
Peach, et al. 2001) (1.3 × 103 – 6.9 × 104 s-1). 
Pressure drop measurements were performed by flowing the solution of interest at a 
constant flow rate from a syringe pump (Genie YA-12, Kent Scientific, Torrington, CT) 
past a digital pressure gauge (Merigauge 3900-GI0100, Meriam Instrument, Cleveland, 
OH) and through microneedle molds. The lower limit of flow rate used in the study was 
determined by the minimum flow rate at which a continuous liquid jet was formed (i.e., 
not discrete droplets). The upper limit was determined by the flow rate at the maximum 
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pressure produced by our pump (i.e., 284 kPa). Measurements for each needle geometry 








To compare the predictive ability of models to experimental data, we determined the 
mean absolute percent error (MAPE) associated with differences between predicted and 
measured dimensionless pressure drop values, defined as the average absolute value of 








PP , (3.1.1) 
where ΔP is the dimensionless pressure drop across the microneedle (predicted or 
measured). 
3.1.2 Numerical Simulation of Fluid Flow in a Microneedle 
To determine the pressure drop across a microneedle as a function of flow rate and 
microneedle geometry, a series of computational fluid dynamics simulations were done 
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using the geometry shown in Figure 3.3A. These simulations were carried out by Prof. 




Figure 3.3 (A) A sketch of the idealized microneedle geometry with relevant dimensions and 
angles: cone half angle θc, tip angle θt, tip diameter Dt, inlet diameter Di, and needle length 
Ln.  The flow enters the microneedle from the left originating from a large plenum chamber 
held at a pressure of p0.  The flow exits at the tip to the local atmosphere held at a constant 
pressure of patm. (B) Microneedle wall profiles for a cone half-angle θc = 20º, a dimensionless 
length L = 10, and four tip angles θt = 0º, 20º, 36.05º, and 60º.  The tip angle θt = 36.05º is the 




from a large plenum and exits through the tip at the right.  The geometry is axisymmetric 
and the microneedle has a curved profile characterized by four parameters: the tip 
diameter Dt, inlet diameter Di, length Ln, and tip angle θt.  From these, the cone half-angle 













arctanθ . (3.1.2) 
 
The curved profile typical of our conically tapered microneedles (see Figure 3.3) was 
mathematically modeled using either a parabola or an ellipse, parameterized mainly by 
the tip angle θt.  The transition between these two shapes occurs at the transition tip 
angle ( ))tan(2arctan cp θθ = .  Thus, the microneedle profile was that of a parabola, 
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ellipse, or straight-sided cone when the tip angle satisfied the relations pt θθ ≤≤0 , 
pt θθ > , or ct θθ = , respectively.  Examples of each of these profiles are shown in 
Figure 3.3B.  The tip diameter was used to scale the geometric parameters and so three 
dimensionless parameters uniquely define this geometry: the dimensionless 
length tn DLL /= , the cone half-angle θc, and the microneedle tip angle θt.   
The flow model was axisymmetric, steady, incompressible, laminar, and Newtonian.  
The viscosity μ and density ρ of the fluid were constant.  The curved inlet to the flow 
domain in the large plenum chamber to the left of the microneedle (not shown in Figure 
3.3A) was held at the constant pressure p0.  The flow outlet at the tip was held at a 
constant atmospheric pressure patm.  Two dimensionless groups characterize the flow in 
the microneedle: the Reynolds number, 
 
μ
ρ tDVRe = , (3.1.3) 









=Δ , (3.1.4) 
where V  is the average velocity at the microneedle tip.   
The simulations were done using the computational fluid dynamics software 
FLUENT (version 6.0, Lebanon, NH).  The dimensionless parameters describing the 
geometry of the microneedle – the length L, tip angle θt, and cone half-angle θc – were 
varied over a wide range that included all experimental values.  For each microneedle 
profile, approximately 100 different flow rates were simulated so that the Reynolds 
 44
number varied over the range 10000 ≤≤ Re .  The plenum size was selected as two inlet 
diameters along the microneedle axis and along the wall, which was large enough so that 
the pressure drop and mass flow rate through the needle were independent of plenum 
size.  Similarly, the mesh size selected was 80 elements per unit length in the 
microneedle, which was large enough that the flow simulations were independent of 
mesh size.  The results reported here are accurate to less than 0.6% uncertainty for Re < 
1, and the error rises to about 3% for Re = 1000.    
3.2 Transdermal Delivery of Insulin 
3.2.1 Solid Microneedles3 
3.2.1.1 Microneedle Fabrication 
Arrays of solid microneedles were fabricated by cutting needle structures from 
stainless steel sheets (SS 304, 75 μm thick; McMaster-Carr, Atlanta, GA) using an 
infrared laser (Resonetics Maestro). Initially, the shape and orientation of the arrays were 
drafted in a CAD file (AutoCAD; Autodesk, Cupertino, CA), which was then converted 
to the file type required by the laser control software (Oregon Microsystems, Beaverton, 
OR). The laser beam traced the desired shape of the needle, which ablated the metal sheet 
and created the needles in the plane of the sheet. The pattern was traced at a rate of 1 
mm/s with a constant 30 psi airflow for cooling and debris removal. The laser was 
                                                 
3 This work was published in Martanto, W., Davis, S. P., Holiday, N. R., Wang, J., Gill, H. S. and 
Prausnitz, M. R. Transdermal delivery of insulin using microneedles in vivo. Pharm Res 21: 947-952 
(2004). 
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operated at 1000 Hz at an energy density of 20 J/cm2 and required approximately 4 min 
to cut an array.  
The metal sheet with needles on it was cleaned in hot soapy water (Alconox, White 
Plains, NY) and rinsed with DI water. Each needle was then manually bent at 90º out of 
the plane of the sheet.  The needles were electropolished in a bath containing a 6:3:1 
mixture by volume of glycerin, phosphoric acid, and water (Fisher Scientific) to remove 
debris (Graham 1971, Hensel 2000). It was operated at 110o C and the sample was 
manually agitated during the polishing process.  The sample was biased with a positive 
charge relative to a copper electrode to generate a current density of 130 mA/cm2.  The 
sample was polished for 2.5 minutes and then rinsed for 15 seconds in DI water followed 
by 15 seconds in 15% nitric acid.  This rinse cycle was repeated and then the entire cycle 
(polishing and rinsing) was repeated for a total polishing time of 5 minutes.  After 
polishing the sample was rinsed with hot water for 1 minute followed by a thorough 
rinsing in DI water. This electropolishing process reduced the needle thickness to 50 μm. 
3.2.1.2 Diabetic Animal Model 
To generate a diabetic animal model, Sprague-Dawley hairless rats (male, 250-350 g, 
Charles River Laboratories, Wilmington, MA) were injected with 100 mg/kg 
streptozotocin (Sigma) in sterile Dulbecco’s phosphate buffered saline without Ca or Mg 
(PBS, pH 7.4; Mediatech, Herndon, VA) by tail vein injection. Over the next day, 
diabetes developed due to destruction of pancreatic islet cells by streptozotocin 
(Tomlinson, Gardiner, et al. 1992). The use of hairless rats in this study was approved by 
the Georgia Tech IACUC and adhered to the NIH "Principles of Laboratory Animal 
Care." The next day, successful induction of diabetes was verified by checking that blood 
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glucose levels were at least 300 mg/dl (Accu-Chek Compact; Roche Diagnostics, 
Indianapolis, IN). Diabetic rats were then anesthetized by intraperitoneal injection of 
1300 mg/kg urethane (Sigma) at a concentration of 200 mg/ml in PBS. Blood glucose 
measurements were obtained using blood samples collected by lateral tail vein laceration. 
After establishing a stable baseline blood glucose level between 300 – 475 mg/dl with 
less than 20% variation over the course of approximately 1 h, the experiments were 
started. 
3.2.1.3 Insulin Delivery Experiments 
To test the ability of microneedles to increase skin permeability to insulin, a 
microneedle array was inserted into the skin at a site on the rat’s lower back using a 
pneumatically-driven insertion device at 30 psi (~ 10 m/s) (Bionic Technologies, Salt 
Lake City, UT). This device was developed to minimize damage during insertion of 
microelectrode arrays into neural tissue and adapted for use on skin (Rousche and 
Normann 1992). Previous studies of microneedles for transdermal drug delivery have 
used similar insertion devices (Matriano, Cormier, et al. 2002). In some cases, the needle 
array was repeatedly inserted (for 10 s) and removed, five times at the same site. A 6-mm 
diameter flanged glass chamber was then adhered to the skin around the array using 
cyanoacrylate glue  (Loctite, Rocky Hill, CT) and filled with a solution containing 
Humulin-R insulin (Eli Lilly, Indianapolis, IN) at a concentration of 100 U/ml unless 
otherwise noted. Microneedles were removed using forceps 10 s, 10 min, or 4 h after 
adding the insulin solution. The insulin solution was kept in the chamber in contact with 
the rat’s skin for 4 h in all experiments. Blood glucose measurements were made every 
30 min by lateral tail vein laceration (Accu-Chek Compact). 
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After the 4-h insulin delivery period, the insulin solution was removed from the skin.  
In some cases, the skin was cleaned with DI water and blood glucose measurements were 
continued every 30 min for another 4 h.  In most cases, 0.2 – 0.5 ml of blood was 
collected using intracardiac puncture or orbital puncture immediately before euthanasia 
using 0.22 ml/kg Beuthanasia (Schering-Plough Animal Health Corporation, Omaha, 
NE). These blood samples were centrifuged at 2040 × g (Eppendorf Centrifuge 5415 C, 
Westbury, NY) for 5 min to collect plasma, which was then stored at -70°C until analysis 
using a human insulin-specific radioimmunoassay (Linco Research, St. Charles, MO) to 
determine plasma levels of insulin delivered to the rats. Because the assay was specific to 
human insulin, it measured only the exogenous insulin delivered to the rat and not the 
rat’s endogenous insulin.  
As a negative control experiment, the same protocol was followed, except no 
microneedles were applied to the skin (i.e., insulin solution was placed passively on the 
skin for 4 h). As positive control experiments, 50 μl of Humulin-R insulin diluted with 
PBS to different concentrations (0.05 U/ml, 0.5 U/ml, and 1.5 U/ml) was administered 
subcutaneously with an insulin syringe and hypodermic needle (29G U-100; Terumo 
Medical, Elkton, MD).  
To facilitate imaging needle penetration pathways within skin, additional experiments 
were performed in which a solution of blue dye (Tissue Marking Dye; Shandon, 
Pittsburg, PA) was placed onto the skin instead of insulin and a 10 s microneedle 
insertion time was used. After 2 min, the dye was washed off the skin surface and a skin 
biopsy was obtained with an 8-mm punch (Tru-Punch; Sklar Instruments, West Chester, 
PA) around the microneedle insertion site and imaged using bright field microscopy 
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(Leica DC 300; Leica Microsystems, Bannockburn, IL). In other experiments, 
microneedles were inserted into skin and a biopsy was taken with the needles remaining 
in the skin. These samples were fixed using 10% neutral buffered formalin for at least 24 
h, dehydrated using ethanol and xylene, and incubated in methyl methacrylate infiltration 
solution (Fisher Scientific) for 72 h before being embedded in methyl methacrylate and 
submerged in water for 48 h (Bancroft and Gamble 2002). Samples were coarse-trimmed 
(Isomet 1000 Precision Saw; Buehler, Lake Bluff, IL) and then sectioned into 200 μm 
strips (Ecomet 3 Variable Speed Grinder; Buehler) before surface staining for 10 s at 55 
ºC (Sanderson’s Rapid Bone; Surgipath Medical Industries, Richmond, IL) and 
examination by bright field microscopy. 
3.2.1.4 Statistical Analysis 
At each condition and time point tested, replicate blood glucose samples from at least 
three different rats were measured, from which the mean and standard deviation were 
calculated. A two-tailed Student’s t-test (α = 0.05) was performed when comparing two 
experimental conditions. When comparing three or more experimental conditions, a one-
way analysis of variance (ANOVA α = 0.05) was performed. A two-way analysis of 
variance (ANOVA α = 0.05) was performed when comparing two factors. In all cases, a 
value of   p < 0.05 was considered statistically significant.  
 49
3.2.2 Hollow Microneedles4 
3.2.2.1 Microneedle Fabrication 
Using the method developed by Dr. Shawn Davis (Davis 2003), hollow metal 
microneedles were fabricated by first creating the molds. Following a similar process to 
make polymer molds (shown in Section 3.1.1), an ultraviolet laser (Resonetics 
Micromaster) operating at 200 Hz with a 248-nm wavelength and a typical energy 
density of 2.0 J/cm2 was used to drill holes through sheets of polyethylene terephthalate 
(Mylar, Dupont).   
To create a tapered geometry hole, the drilling program was set to trepan, or trace, a 
circular path with a diameter less than the diameter of the laser beam. Strong laser 
fluence generated in the center and an annular region of weaker fluence generated around 
it, produced a tapered hole.  To achieve a needle mold with a desired base diameter (dbase) 
and tip diameter (dtip), the following expressions were used to determine the required 







=     (3.2.1) 
tipbeamtrepan ddd −=     (3.2.2) 
These parameters, combined with the thickness of the Mylar substrate, which 
governed the needle mold length, determined the final microneedle geometry. The 
geometry used for in vivo experiments in this study had a 300-μm base diameter and a 
                                                 
4 This work was carried out in collaboration with Dr. Shawn Davis and was published in Davis, S. P., 
Martanto, W., Allen, M. G. and Prausnitz, M. R. Hollow metal microneedles for insulin delivery to diabetic 
rats. IEEE Trans Biomed Eng 52: 909-915 (2005). 
 50
75-μm tip diameter through a 500-μm sheet. This corresponded to a 187.5-μm beam 
diameter and a 112.5-μm trepan diameter.  
To allow electroplating of the insulating polymer mold, a titanium-copper-titanium 
(with 35 nm, 650 nm and 35 nm thickness, respectively) seed layer was then deposited on 
the top and sidewalls of the polymer molds using direct current sputtering (CVC 601, 
Rochester, NY).  Nickel was electroplated onto the mold to create a microneedle using a 
Watts formulation bath (Technic, Cranston, RI) at 54oC (Schlesinger and Paunovic 2000) 
at a nickel deposition rate of approximately 10 μm/hr. The voltage was adjusted to 
maintain a constant current density of 10 mA/cm2. Plating proceeded for 5 min under 
these conditions to form the initial “strike” layer on the mold.  The mold was then 
removed from the bath and rinsed in DI water.  A sheet of powder coating tape (Shercon, 
Santa Fe Springs, CA) was then placed across the bottom of the mold to prevent over-
plating at the microneedle tip due to current crowding. The duration of plating 
determined the thickness of the microneedle walls and the array’s base. 
Metal microneedle arrays were released from polymer molds in the final step of 
fabrication.  Mylar molds were removed in a concentrated caustic solution (1 N, NaOH, 
boiling) after approximately 20 min for a 500-μm thick mold.   
3.2.2.2 Insulin Delivery Experiments 
To assess the ability of hollow microneedles to delivery insulin and modulate blood 
sugar levels in a diabetic animal (diabetic induction is the same as the one described in 
Section 3.2.1.2), an array of hollow microneedles (fabricated methods described in 
Section 3.2.2.1) was inserted into the skin of an anesthetized, diabetic, hairless rat 
(insertion method described in Section 3.2.1.3). In this set-up, drug solution was not in 
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direct contact with skin; insulin could transport into the skin only through the hollow 
bores of the microneedles.  As a negative control experiment, the same protocol was 
followed, except no microneedles were applied to the skin (i.e., insulin solution was 
placed passively on the skin for 4 h). As positive controls, 0.05 and 0.5 U of insulin were 
injected subcutaneously using a 29-gauge hypodermic needle and syringe. To measure 
changes in blood glucose level, 10-μl blood samples were collected by tail vein laceration 
every 30 min for 8 h and assayed using a glucose test strip (Accu-Chek Compact).  
Insulin was kept in the reservoir during a 4-h delivery period, after which the reservoir 
was emptied and rats were monitored for an additional 4 h. 
In a separate set of experiments, plasma insulin concentration was measured by 
collecting two 0.5-ml blood samples: an orbital collection 30 min after starting insulin 
delivery and an intracardiac collection at 4 h.  Blood samples were immediately 
centrifuged at 2040×g (Eppendorf Centrifuge 5415C) for 5 min and the plasma was 
stored at -70 oC.   The concentration of human insulin (i.e., Humulin R) was determined 
by radioimmunoassay (Linco Research). 
3.3 Microinfusion Using Hollow Microneedles 
3.3.1 Glass Microneedle Fabrication 
Although microneedles can be mass-fabricated using a variety of different methods as 
single needles and multi-needle arrays made of a variety of different materials 
(McAllister, Allen, et al. 2000, Reed and Lye 2004), we used single, glass microneedles 
in this study because they can be quickly produced in various geometries for small-scale 
laboratory use, are physiologically inert, and permit easy visualization of fluid flow. 
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Glass microneedles were fabricated by pulling fire-polished borosilicate glass pipettes 
(o.d. 1.5 mm, i.d. 0.86 mm, BF150-86-15, Sutter Instrument, Novato, CA) using a 
micropipette puller (P-97, Sutter Instrument). In most cases, the resulting blunt-tip 
microneedles were then beveled (BV-10, Sutter Instrument) and cleaned using chromic 
acid (Mallinckrodt, Hazelwood, MO), followed by filtered DI water and acetone (J. T. 
Baker, Phillipsburg, NJ) rinses. Microneedle geometries were determined by bright-field 
microscopy (Leica DC 300) and image analysis (Image Pro Plus, version 4.5, Media 
Cybernetics, Silver Spring, MD). Microfabricated microneedles used in this study 
typically had an effective tip opening radius of 22 – 48 μm with a tip bevel angle of 35 – 
38º. Because the opening of a bevel-tip microneedle is oval in shape, the effective radius 
was determined as the average of the half-lengths of the long and short axes of the 
ellipse.  
3.3.2 Skin Preparation 
Human abdominal skin was obtained from cadavers from the Emory University Body 
Donor Program and stored at -80 °C (Revco Ultima II, Kendro Laboratory Products, 
Asheville, NC). After warming to room temperature and removing subcutaneous fat, skin 
was hydrated in a Pyrex dish filled with phosphate-buffered saline (PBS; Sigma) for at 
least 15 min prior to use.  The skin was then cut into 4 cm x 4 cm pieces and stretched 
onto a stainless steel specimen board with eight tissue-mounting pins on it to mimic the 
tension of living human skin.  
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3.3.3 Infusion Experiments 
To measure flow rate into skin during microneedle infusion, a single microneedle was 
inserted into human cadaver skin to microinfuse sulforhodamine solution and the infusion 
flow rate was measured over time. As an aid to visualizing flow into skin, 
sulforhodamine-B dye (Molecular Probes, Eugene, OR) was added to PBS, stirred, and 
filtered (0.2 μm pore size, Nalge Nunc International, Rochester, NY) to make 1 x 10-3 M 
sulforhodamine solution. Either a 250 μl or 1 ml glass syringe (Gastight Syringe, 
Hamilton Company, Reno, NV) was used as the reservoir for sulforhodamine solution 
and connected to a high-pressure CO2 gas tank (Airgas, Radnor, PA) on one end and 
connected to a 2.1-mm i.d. metal tubing line on the other end, which was then connected 
to the end of a microneedle using a short, flexible tubing linker. A custom-made, rotary-
threaded device (Wang, Cornwell, et al. 2005) was used to hold the microneedle and 
allow microneedle insertion into and retraction out of the skin in a controlled fashion 
calibrated by the number of rotations of the device (i.e., 1 full rotation = 1440 μm needle 
displacement). This assembly was held by a stainless steel adapter attached to a Z-stage 
(Graduated Knob Unislide, Velmex, Bloomfield, NY) to control vertical motion of the 
microneedle holder with ±10 μm resolution.  
The flow rate of sulforhodamine solution microinjection was determined by following 
movement of the gas-liquid meniscus in the syringe reservoir over time with a digital 
video camera (DCR–TRV460, Sony, Tokyo, Japan) and image analysis software (Adobe 
Photoshop 7.0, Adobe Systems, San Jose, CA) after converting the captured movie into 
sequences of still images (Adobe Premiere 6.0, Adobe Systems). After initially 
positioning the gas-liquid meniscus at the top of the glass syringe by injecting an 
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appropriate amount of air upstream from the syringe, the microneedle was lowered until 
its tip touched the skin sample.  The microneedle holder was then rotated clockwise to 
insert the microneedle to the desired insertion depth and sometimes rotated 
counterclockwise to retract the microneedle to the desired retraction distance. The 
experimental setup is shown in Figure 3.4 below. 
The gas pressure was then set to the desired infusion pressure using a pressure 
regulator (Two-Stage Regulator, Fisher Scientific) on the CO2 cylinder and the 






Figure 3.4 (A) Schematic of experimental set up for microinfusion using microneedles. A 
glass microneedle is held in place by a rotary-threaded device. This assembly is held by a 
stainless steel adapter attached to a Z-stage. The end of the microneedle is connected to a 
metal tubing line using a flexible tubing linker. The metal tubing line is connected to a glass 
syringe reservoir on the other end which is connected to a high-pressure CO2 tank. (B) 





During the experiment, the skin was examined for fluid leakage, which was easily visible 
due to the presence of sulforhodamine dye in the fluid. If there was no leakage, then the 
flow rate within the glass syringe was assumed to be the same as the flow rate into the 
skin. This assumption was validated by preliminary experiments that quantified the 
sulforhodamine content of skin after microinjection using spectrofluorimetry after 
chemically digesting the skin. These measurements demonstrated that the amount of 
sulforhodamine within the skin was approximately the same as the amount displaced in 
the syringe source (data not shown). Data were discarded in those few cases (< 5%) 
where leakage was observed. 
To serve as a base case experiment, a bevel-tip microneedle with 30-μm effective 
opening radius was inserted to a depth of 1080 μm into the skin and microinfusion flow 
was initiated by applying a constant infusion pressure of 138 kPa. Every 5 min, the 
needle was retracted 180 μm back toward the skin surface to a final insertion depth of 
180 μm (relative to its initial position prior to insertion). The infusion flow rate was 
measured every minute with a 5 s offset at the beginning and the end of each period at a 
given retraction position (i.e., at 5 s, 60 s, 120 s, 180 s, 240 s, and 295 s).  
To determine the effect of microneedle insertion depth and retraction distance on flow 
rate, the base case experiment was compared to otherwise identical experiments using 
900-μm and 720-μm initial insertion depths followed by 180-μm retraction every 5 min. 
The effect of infusion pressure was determined by comparing to pressures of 69 and 172 
kPa. The effect of tip bevel was determined by comparing to a blunt-tip microneedle with 
the same opening (i.e., 31 μm radius) as the bevel-tip microneedle.  The effect of 
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microneedle tip opening size was determined by comparing to needles with smaller (22 
μm radius) and larger (48 μm radius) tip openings. The effect of hyaluronidase was 
determined by comparing to an infusion fluid containing 200 U/ml hyaluronidase 
prepared by mixing 3 ml of hyaluronidase solution (Vitrase®, 200 U/ml, ISTA 
Pharmaceuticals, Irvine, CA) with 7 ml of 1 x 10-3 M sulforhodamine solution. Finally, 
the effect of infusion time was determined over longer times by inserting the microneedle 
to a depth of 1080 μm and either leaving it in place or retracting 720 μm to a final 
insertion depth of 360 μm and measuring flow rate for 104 min.  
3.3.4 Histological and Microscopic Image Analysis 
After each infusion experiment, the top surfaces and undersides of the skin were 
imaged using bright-field microscopy (Leica DC 300) to visualize the distribution of 
sulforhodamine infusion. Additional experiments were performed for detailed 
histological imaging of microneedle penetration pathways and injection within skin. For 
these experiments, a microneedle with 30-μm effective radius opening and 38º bevel 
angle was externally spray-coated (Testor Corporation, Rockford, IL) using a solution of 
red dye (Tissue Marking Dye; Triangle Biomedical Sciences, Durham, NC ) thickened 
using 2 x 10-2 M polyvinylpyrrolidone (Aldrich, St. Louis, MO). The needle was then 
inserted to a depth of 1080 μm into the skin and retracted 720 μm to a final insertion 
depth of 360 μm. A solution containing 2.1 x 108 particles/ml of 6-μm yellow-green 
fluorescence-labeled polystyrene microspheres (Fluoresbrite® YG, Polysciences, 
Warrington, PA) mixed with blue-green dye (Triangle Biomedical Sciences) was injected 
at 138 kPa infusion pressure until the dye became visible within the skin (~1 min infusion 
time). These skin samples, with microneedles in place, were fixed using 10% neutral 
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buffered formalin (Fisher Scientific) or a mixture of 2% paraformaldehyde and 2% 
glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) for at least 24 h before 
rinsing thoroughly with PBS and then submerging in sterilized, filtered, 30% sucrose 
overnight (Bancroft and Gamble 2002). The skin samples were frozen in liquid nitrogen 
with optimal cutting temperature compound (Tissue-Tek, Sakura Finetek, Torrance, CA) 
in an embedding mold container and later sectioned into 10-μm thick slices using a 
cryostat (Cryo-star HM 560MV, Microm, Waldorf, Germany). Histological sections were 
surface stained with hematoxylin and eosin (Autostainer XL, Leica Microsystems) and 
examined by bright field (Leica DC 300) and fluorescence microscopy (Eclipse E600W, 
Nikon, Melville, NY).  
3.3.5 Statistical Analysis 
Flow rate measurements at each condition and time point were performed using at 
least three skin specimens, from which the mean and standard deviation were calculated. 
A two-tailed Student’s t-test (α = 0.05) was performed when comparing two 
experimental conditions. When comparing three or more experimental conditions, a one-
way analysis of variance (ANOVA α = 0.05) was performed. A two-way analysis of 
variance (ANOVA α = 0.05) was performed when comparing two factors. In all cases, a 










4.1 Fluid Dynamics of Microneedles5 
Toward achieving painless injections and other microfluidic applications, we 
microfabricated conically tapered needles of micron dimensions. The relationship 
between pressure drop and flow rate through microneedles was experimentally quantified 
as a function of fluid viscosity and microneedle length, diameter, and cone half-angle. At 
Reynolds numbers less than approximately 100, dimensionless pressure drop (2ΔP/ρv2) 
decreased steeply with increasing Reynolds number, indicating the importance of viscous 
forces. At larger Reynolds numbers, the flow was almost inviscid, as indicated by a weak 
dependence of dimensionless pressure drop on Reynolds number. Numerical simulations 
showed good agreement with experimental data and predicted that flow through conically 
tapered microneedles is primarily controlled by the diameter and taper angle at the 
microneedle tip.  A characteristic feature of flow through conically tapered microneedles 
is a favorable axial pressure gradient that accelerates fluid through the microneedle, thus 
inhibiting growth of the viscous boundary layer on the microneedle wall.  
 
4.1.1 Introduction 
To extend microneedle capabilities to actively deliver drugs by convection, we more 
recently fabricated hollow microneedles that could be coupled with a pump or syringe for 
                                                 
5 This work was carried out in collaboration with Prof. Marc Smith and was published in Martanto, W., 
Smith, M. K., Baisch, S. M., Costner, E. A. and Prausnitz, M. R. Fluid dynamics in conically tapered 
microneedles. AIChE J 51: 1599-1607 (2005). 
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injection. Hollow microneedles were initially made by photolithography and plasma 
etching (McAllister 2000), but our current approach involves laser drilling polymeric 
molds and electrodepositing metal onto the molds (Davis, Prausnitz, et al. 2003). These 
microneedles have been shown to permit flow of fluid and insert into skin (Davis, Landis, 
et al. 2004, McAllister, Wang, et al. 2003). Others have also studied fabrication and 
applications of hollow microneedles (Gardeniers, Luttge, et al. 2003, Stoeber and 
Liepmann 2000). 
The pressure drop required to flow fluid through a microneedle depends on needle 
geometry and fluid viscosity and density. Needles of micron dimensions can exhibit 
significant resistance to flow. Measurement and prediction of microneedle fluid dynamics 
is needed to design needles that balance between geometries small enough to avoid pain, 
sharp enough to easily insert into skin, and large enough to permit useful flow rates at 
reasonable pressures. To address this need, this study sought to experimentally quantify 
the relationship between pressure drop and flow rate as a function of microneedle 
geometry and fluid viscosity, and to use computer simulations to model fluid dynamics in 
microneedles. 
Flow through microneedles is characterized by (i) micron dimensions, (ii) conically 
tapered channels, and (iii) flow over a broad range of Reynolds numbers that can span at 
least 1 – 1000. To gain perspective from the literature, there are numerous studies of fluid 
flow inside microchannels (Stone and Kim 2001, Trebotich, Zahn, et al. 2003), but we 
are not aware of any that address flow through conically tapered geometries. Fluid flow 
through macroscopic conical channels has been addressed in the literature, but primarily 
for developed flow in long channels. Approximate analytical solutions have been derived 
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for short channels with the assumption of creeping flow, limited contraction factor, and 
small taper angle (Kwon, Shen, et al. 1986, Nishimura and Oka 1965, Oka 1964, Sutterby 
1964), which may not apply to microneedles.  
These theoretical approaches have been validated macroscopically using only limited 
or no data and have not been validated at microscopic dimensions. The experimental data 
that do exist (Kemblowski and Kiljanski 1975), as well as the more extensive numerical 
analysis of fluids in conical channels (Garrioch and James 1997, Jarzebski and Wilkinson 
1981), is almost exclusively at low Reynolds numbers, where viscous effects dominate 
inertial effects. For this reason, our data can also be used to validate previous analytical 
and numerical predictions from the literature. 
To determine if needles of micron dimensions can be used to transfer fluids for 
injecting drug solutions into skin or for other microfluidic applications, we flowed liquids 
through microneedle molds and measured the pressure drop required as a function of 
microneedle geometry and fluid viscosity.  Conically tapered microneedle molds used in 
this study were laser drilled using microfabrication techniques, as shown in Figure 3.1.   
4.1.2 Measurement of Pressure Drop versus Flow Rate 
One of the goals for this study was to quantify the relationship between flow rate and 
pressure drop as a function of microneedle geometry. We made these measurements 
using 22 different needle geometries each at 4 – 7 different flow rates for a total of 153 
measurements.  The range of geometries considered spanned inlet diameters of Di = 102 
– 412 µm, tip diameters of Dt = 20 – 96 µm, cone half-angles of θc = 5 – 20º and lengths 
of Ln = 100 – 500 µm.   
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Figure 4.1 shows the raw data measured from a representative set of individual 
microneedles (each having the same cone half-angle, but different diameters and lengths). 
It shows that pressure drop increased in a nonlinear manner with increasing flow rate and 
with decreasing tip diameter Dt.  For this representative set of microneedle geometries, 
only modest pressures were required to achieve flow rates of many microliters per second 
per needle, which may be of interest for drug delivery applications.  Over the full range 
of microneedle geometries considered, pressure drops of 4.6 – 196.5 kPa were required to 




Figure 4.1 Pressure drop required for flow of water through representative microneedles of 
different geometries as a function of flow rate.  Three different needle geometries each with 
the same cone half-angle, θc = 15˚, but with different tip diameter (Dt), inlet diameter (Di), 
and length (Ln) are compared:  (■)Dt = 42 μm, Di = 162 μm, Ln = 225 μm, (▲)Dt = 50 μm, Di 





Nondimensionalized data for all 22 microneedle geometries tested are shown together 
as dimensionless pressure drop ΔP versus Reynolds number Re in Figure 4.2. Albeit with 
some scatter, the data collapse into a set of similar curves, which show the characteristic 
transition from a viscously dominated flow at small Reynolds number, where 
dimensionless pressure decreases inversely with Reynolds number, to an inertially 
dominated flow at large Reynolds number, where dimensionless pressure is relatively 
independent of Reynolds number. Most data were generated using water as the fluid, but 
a sub-set of data points used water-glycerin solutions with elevated viscosity (1 – 9.8 




Figure 4.2 The dimensionless pressure drop versus Reynolds number for flow in conical 
microneedles.  The circles mark all experimental data points.  The two solid lines are the 
results from numerical simulations for straight-sided cones with dimensionless length 






4.1.3 Comparison of Experimental Data to Theoretical Predictions  
Another goal of this study was to determine if theoretical expressions developed in 
previous studies that modeled flow through conical channels could predict our 
experimental measurements in microneedles. We identified three theoretical approaches 
and one numerical simulation that are representative of the scope of published literature 
on this topic.  
The three theoretical approaches showed varying levels of agreement with our 
experimental measurements. Kemblowski (Kemblowski and Kiljanski 1975) modeled 
fluid flow through a conical geometry by assuming that the axial velocity profile at each 
axial location was similar to the Poiseuille velocity profile for flow in a circular tube.  
This model is most valid in the slow-flow limit, where Re < 1, and for small cone half-
angles. It yielded a mean absolute percent error (MAPE) of 52%, meaning that 
predictions were on average within ± 52% of our experimental values. Nishimura 
(Nishimura and Oka 1965) computed an approximate solution to the flow equations in a 
conical geometry using a series expansion of the velocity based on inverse powers of the 
radial distance from the virtual vertex of the cone. This solution produced a small inertial 
correction to the flow field, but they showed that this correction did not influence the 
flow rate.  Thus, their result is equivalent to the slow-flow limit, and it yielded a MAPE 
value of 67%.  Both of these flow models are most accurate in the small-Reynolds-
number limit Re < 1, and this explains their failure to accurately predict our data, which 
lies in the Reynolds number range 28 < Re < 1000.   
In contrast, Sutterby (Sutterby 1964) developed an equation for the pressure drop in a 
non-Newtonian conical flow by simply adding the relevant numerical solution in the 
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slow-flow limit with the inviscid solution in the large-Reynolds-number limit.  This 
approach, which yielded a MAPE value of 30%, worked better than the previous two 
approaches since most of our data lies in the large-Reynolds-number range where inertial 
forces dominate the flow.  Jarzebski (Jarzebski and Wilkinson 1981) performed a finite-
difference solution of the governing equations of motion for the flow in a tapered tube 
with a parabolic velocity profile at the entrance.  They used the result to develop a 
pressure-drop correlation based on the Stokes-flow solution of Harrison (Harrison 1919). 
The correlation was within 5% of their numerical results for Reynolds numbers less than 
750 and cone half-angles less than 7º.  The approach yielded a MAPE value of 48% with 
respect to our data.  It did not perform as well as Sutterby’s result because the cone half-
angle in our microneedles was in the range 5º < θc < 21º and because of the different 
entrance geometry and flow present in our experiments.  
4.1.4 Numerical Simulation of Fluid Flow in a Microneedle 
To further study the effects of microneedle geometry on the dynamics of flow 
through a microneedle, we developed a model appropriate for our experimental 
conditions in collaboration with Prof. Marc Smith, who performed numerical simulations 
over a broad range of conditions to produce curves expressing the dimensionless pressure 
drop ΔP as a function of the Reynolds number Re, with the dimensionless length L, cone 
half-angle θc, and tip angle θt as parameters.  In our first set of results, microneedles were 
modeled as straight-sided cones with cone half-angles ranging from θc = 5 – 20º, as 
determined from experimental measurements of microneedle geometry (see above).  
Figure 4.2 shows all of the experimental data together with the predicted dimensionless 
pressure drop versus Reynolds number curves for the smallest and largest cone half-
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angles.  These numerical curves approximately bound the experimental data.  A more 
quantitative assessment of the simulation’s predictive ability was produced by comparing 
errors between each individual predicted data point and its corresponding measured 
value, which yielded a MAPE of 11% for the whole data set.   
4.1.4.1 Effect of Microneedle Length L 
Simulation results were next used to predict the effect of microneedle geometry on 
dimensionless pressure drop at different Reynolds numbers in greater detail.  The effect 
of needle length was considered first.  As a base case, the dimensionless pressure drop for 
a cylindrical microneedle (i.e., not tapered, θc = 0) is shown at four different lengths in 
Figure 4.3.  The dimensionless pressure drop decreases monotonically with Reynolds 
number and increases with length. As 0→Re , each curve approaches the well-known, 
Hagen-Poiseuille result of ( )LReLfP /64==Δ  for fully developed, laminar pipe flow, 
where f is the Darcy friction factor (Munson, Young, et al. 2002). As ∞→Re , all curves 
approach the limiting value of one for purely inviscid flow.  However, for Reynolds 
numbers as large as 1000, the dimensionless pressure drop continues to vary with length 
and is significantly greater than the purely inviscid result.  This is due to the developing 
entrance flow in these microneedles. The dimensionless distance required to establish a 
fully developed, laminar flow in a cylindrical pipe is the dimensionless entrance length 
(Munson, Young, et al. 2002) tee DLL /
* =  = 0.06 Re.  For Re = 1000, the entrance length 




Figure 4.3 The effect of microneedle length on dimensionless pressure drop versus Reynolds 




the large Reynolds number behavior in Figure 4.3 is due to the developing boundary 
layer in the needle.   
In contrast to cylindrical microneedles, there is very little effect of needle length 
on flow through microneedles with tapered sides (Figure 4.4).  Tapered microneedles are 
of interest because their sharper tips permit easier insertion into skin (Davis, Landis, et al. 
2004). Figure 4.4 shows the results for a cone-shaped microneedle with a straight-sided 
taper (θt = θc), a cone half-angle θc = 5º, and four different lengths.  There is still a 
significant variation in the dimensionless pressure drop with Reynolds number, but the 
dependence on needle length L is small.   At larger cone half-angles, the curves for the 
four different lengths are indistinguishable (data not shown). The reason why 
dimensionless pressure drop in tapered needles is largely independent of needle length L 




Figure 4.4 The effect of microneedle length on dimensionless pressure drop versus Reynolds 
number for a tapered, straight-sided cone with θc = 5º having dimensionless lengths L = 2.5, 
5, 10, and 20. The three curves for dimensionless length L ≥ 5 are almost indistinguishable. 
 
 
4.1.4.2 Effect of Cone Half-Angle θc and Tip Angle θt 
To assess the effect of cone half-angle θc on microneedle fluid dynamics, Figure 4.5 
shows the dimensionless pressure drop for microneedles with a straight-sided profile (θt = 
θc) and with various values for the cone half-angle θc.  Because dimensionless pressure 
drop is almost independent of microneedle length for geometries of interest (i.e., θc ≥ 5º), 
microneedle length was set to a representative value of L = 10.  The simulations show 
that dimensionless pressure drop decreases with increasing Reynolds number and 
increasing cone half-angle, especially between θc = 0º (a straight cylinder) and θc = 5º 




Figure 4.5 The effect of microneedle taper on dimensionless pressure drop versus Reynolds 
number for a straight-sided cone (θc = θt) with cone half-angles θc = 0º, 5º, 10º, 20º, and 30º 




The data from Figure 4.5 indicate that the cone half-angle for a straight-sided conical 
microneedle is an important parameter.  However, the geometry of a straight-sided cone 
(θt = θc) is not representative of most microneedles used in this study, which have tapered 
sides with curved profiles (Figure 3.1B).  To address this complexity, microneedle 
sidewall profiles were modeled as either parabolas or ellipses with a specified tip angle θt 
that could be varied independently from the cone half-angle θc, as described in the 
numerical methods section (see Figure 3.3).  Tip angle is explicit in this model, because 
of our expectation that most of the pressure drop occurs near the tip of the microneedle, 
which is validated and discussed below.   
To de-couple the effects of cone half-angle and needle tip angle, the tip angle was 




Figure 4.6 The effect of microneedle taper on dimensionless pressure drop versus Reynolds 
number for a microneedle with a curved profile with cone half-angles θc = 5º, 10º, 20º and 
30º, a fixed tip angle θt = 20º and dimensionless length L = 10.  The curves for the three 




The dimensionless pressure drop for a cone half-angle θc = 5º is slightly larger than the 
others, but the three curves for θc = 10º, 20º, and 30º are nearly indistinguishable.  In 
contrast, when cone half-angle is held constant (θc = 20º) and tip angle is varied, the 
dimensionless pressure drop varies strongly with tip angle (Figure 4.7). This is consistent 
with the expectation that pressure drop is controlled largely by fluid dynamics at the 




Figure 4.7 The effect of microneedle taper on dimensionless pressure drop versus Reynolds 
number for a microneedle with a curved profile with tip angles θt = 0º, 5º, 10º, 20º, 30º, 40º, 




Possibly the most interesting aspect of the data in Figure 4.7 is that there is a 
minimum in the dimensionless pressure drop as a function of tip angle. For example, 
when Re = 1000, the minimum dimensionless pressure drop occurs when the tip angle is 
near θt = 20º, which is when the microneedle has the profile of a straight-sided cone (θt = 
θc).  The tip angle for minimum dimensionless pressure drop depends on the Reynolds 
number, e.g., θt ≈ 30º when Re = 400 and θt ≈ 40º when Re = 200.  Almost identical 
results for the pressure drop occurred when other cone half-angles and needle lengths 
were considered, because the pressure drop does not depend very strongly on these 
parameters (data not shown, but see above). The pressure drop is minimized when the 
needle is nearly a straight-sided cone because the flow is accelerated towards the tip in a 
manner that almost optimally reduces viscous boundary layer growth and losses, as 
discussed below.  When θt < θc, the boundary layer grows more near the needle tip. This 
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increases viscous friction and pressure drop in the microneedle.  When θt > θc, viscous 
friction and pressure drop increase because of the more abrupt transition for the exit flow.   
This same conclusion can be obtained by computing the dimensionless mass flow rate 










& ,   (4.1.1) 
where am&  is the dimensional mass flow rate, At is the tip area, and atmppp −=Δ 0  is the 
dimensional pressure drop across the microneedle.  For four representative tip angles 
plotted in Figure 4.7, the dimensionless mass flow rates are m& = 0.7544, 0.8811, 0.8809, 
and 0.8494 corresponding to θt = 0º, 20º, 40º, and 60º, respectively.  The peak in the mass 
flow rate is rather broad, but the maximum value occurs near the tip angle of 20º, which 
corresponds to the geometry of a straight-sided cone (θt = θc).  
4.1.4.3 Pressure Profile along Microneedle Axis 
Altogether, the results from Figure 4.3 – Figure 4.7 show that the dimensionless 
pressure drop in a tapered microneedle depends weakly on the dimensionless length L 
and the cone half-angle θc, depends strongly on the tip angle θt, and is minimized when 
the needle profile is nearly a straight-sided cone (θt = θc).  The reasons for this can be 
better understood by examining the pressure variation along the axis of the microneedle, 
which is most conveniently discussed in terms of a different scaling than that used for the 
dimensionless pressure drop PΔ  defined in Equation 3.1.4.   
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This new dimensionless pressure is scaled with the total pressure drop across the 










*  (4.1.2) 
Figure 4.8 shows this dimensionless pressure versus the dimensionless distance x 
(nondimensionalized relative to needle tip diameter, Dt) along the axis of the microneedle 
for four different tip angles, with constant cone half-angle θc = 20º, dimensionless length 
L = 10, and Reynolds number Re = 500.  Over 95% of the total pressure drop occurs in 
the last 40% of the length of the microneedle when θt = 0º and in the last 20% or less 
when θt ≥ 20º.  These results show that the largest pressure variations in the microneedle 
are determined primarily by flow near the tip.  In our model, tip geometry is strongly 
dependent on the tip angle θt and only weakly dependent on the dimensionless length L 
and cone half-angle θc.  This explains why the tip angle is the primary parameter 





Figure 4.8 The scaled pressure P* (see text Equation 4.1.2) versus the dimensionless distance 
x along the axis for flow in microneedles showing the effect of tip angle θt = 0º, 20º, 40º and 
60º.  The dimensionless pressure drops for these microneedles are ΔP = 1.757, 1.288, 1.289 
and 1.386, respectively. The dimensionless mass flow rates are m& = 0.7544, 0.8811, 




The pressure profile in the microneedle for an incompressible, large Reynolds number 
flow (as shown in Figure 4.8) is primarily an inviscid flow effect.  As the cross-sectional 
area of the microneedle decreases, fluid velocity increases and pressure decreases.  The 
inviscid portion of this pressure drop is a result of fluid acceleration.  The viscous portion 
results from the growth of the viscous boundary layer along the wall of the microneedle.  
Near the tip of the microneedle, the large pressure variation causes a favorable pressure 
gradient that slows the growth of the boundary layer, thereby confining viscous effects 
closer to the wall and reducing the viscous portion of the pressure drop.  However, if the 
tip angle is too large, the abrupt change in flow geometry at the tip introduces additional 
frictional effects that increase the viscous portion of the pressure drop (simulation data 
not shown). 
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The relative importance of viscous effects on pressure drop across a microneedle was 
determined using an inviscid flow model with a concentrated tip resistance.  In this 
model, the flow is steady, the fluid density is constant, and the velocity is unidirectional 
and uniform across each cross-section of the microneedle.  The flow is inviscid from 
inside the plenum to just before the tip of the microneedle.  The concentrated tip 
resistance produces a discrete pressure drop at the tip whose value is chosen so that the 
mass flow rate in the inviscid model is the same as that of the viscous flow in the 
numerical simulations for a given Reynolds number.  Writing the fluid velocity in the 
microneedle in terms of the mass flow rate and using Bernoulli’s equation for the 









−= ,   (4.1.3) 
where D(x) is the dimensionless local diameter of the microneedle (scaled on the tip 
diameter Dt) and m&  is the dimensionless mass flow rate defined in Equation 4.1.1.  The 
largest dimensionless mass flow rate, 1max =m& , occurs when the tip resistance is zero 
(i.e., the flow is inviscid) and it is independent of the shape or length of the microneedle.  
Viscous friction, as represented by the tip resistance, always decreases the flow rate.   
Figure 4.9 shows a comparison of the pressure profiles in a microneedle obtained 
from the numerical simulations (solid curves) and from the inviscid flow model (dashed 
curves) for three tip angles.  The distance between the two curves for each tip angle 
represents the reduction in pressure caused by viscous friction.  Viscous effects increase 
in magnitude and extend farther from the tip when the tip angle is close to zero.  Viscous 
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Figure 4.9 The scaled pressure P* (see text Equation 4.1.2) versus the dimensionless distance 
x along the axis for flow in microneedles showing the effect of viscous losses.  The solid lines 
are from the numerical simulations that include viscous and inertial effects, whereas the 
dashed lines are from the inviscid flow model with a tip resistance. The distance between 
the two curves in each pair represents the effect of viscous friction. These microneedles have 
tip angles θt = 0º, 20º and 60º.  The dimensionless pressure drops for these microneedles are 
ΔP = 1.757, 1.288 and 1.386 respectively. The dimensionless mass flow rates are m& = 0.7544, 
0.8811 and 0.8494 respectively.  All geometries have fixed Reynolds number Re = 500, cone 
half-angle θc = 20º, and dimensionless length L = 10. 
 
 
4.1.4.4 Statistical Fit of Simulation Results To Predict Pressure Drop 
The results of these numerical simulations demonstrated that the dimensionless length 
L, the cone half-angle θc, and even the profile of the microneedle are not very important 
parameters in determining the overall pressure drop for flow through a microneedle, 
provided the cone half-angle θc is greater than about 5º or 10º.  This leaves the Reynolds 
number and the tip angle θt as the primary parameters needed to characterize the pressure 
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drop, as shown in Figure 4.7.  To make these results more useful for the design of 
microneedles, simulation data from Figure 4.7 were fitted to the following functional 
form,  
 ( ) 11 ++=Δ cbaRe
Re
KP , (4.1.4) 
where K, a, b, and c are parameters that depend only on the tip angle θt.  The values of 
these four parameters are given in Table 1 for microneedles with tip angles in the range 
0 ≤ θt ≤ 60º, a cone half-angle θc = 20º, and a dimensionless length L = 10.  Over the 
Reynolds number range 0.1 ≤ Re ≤ 1000, this correlation is accurate with respect to the 
numerical results to less than 1% uncertainty for tip angles in the range 0º ≤ θt ≤ 35º and 
to no more than 1.7% for tip angles in the range 35º < θt ≤ 60º.  For the restricted 
dimensionless pressure drop range 1 ≤ ΔP ≤ 2, the correlation is accurate to less than 
0.5% for tip angles in the range 0º ≤ θt ≤ 30º and to no more than 1% for tip angles in the 











Table 1. Parameters for Equation 4.1.4, which correlates the dimensionless pressure drop 
with the Reynolds number as a function of the tip angle θt.    
 
θt K a b c 
0º 118.33 0.0181 1.065 0.435 
5º 75.69 0.0280 1.040 0.408 
10º 54.67 0.0372 1.029 0.399 
15º 43.00 0.0447 1.007 0.412 
20º 36.05 0.0496 0.969 0.452 
25º 31.74 0.0514 0.922 0.518 
30º 29.06 0.0507 0.877 0.607 
35º 27.47 0.0486 0.839 0.710 
40º 26.78 0.0459 0.810 0.816 
45º 26.67 0.0435 0.791 0.912 
50º 27.01 0.0417 0.779 0.993 
55º 27.75 0.0407 0.772 1.053 














Overall, the experimental data from this study of conically tapered microneedles were 
consistent with the well-known behavior of internal flows.  When all of the pressure-drop 
data for different needle geometries and fluid viscosities were nondimensionalized, they 
collapsed into a set of similar curves that were a function of the Reynolds number (Figure 
4.2).  These curves exhibited the characteristic creeping-flow limit at small Reynolds 
number, in which the dimensionless pressure drop is inversely proportional to the 
Reynolds number, and the characteristic inviscid-flow limit at large Reynolds number, in 
which the dimensionless pressure is independent of Reynolds number. 
Numerical simulations revealed additional complexities to the flow due to the 
needle’s tapered geometry and short length. The most significant finding is that the 
pressure drop required to flow fluid through a microneedle is controlled primarily by the 
tip angle θt (Figures 4.5 – 4.7) and tip diameter Dt (found in the Reynolds number).  This 
is because the microneedle flows in this study were not fully developed. Each 
microneedle was so short that the viscous boundary layer on the interior wall did not 
grow to the point of merger. This behavior was also aided by the tapered geometry that 
created a favorable axial-pressure gradient that inhibited boundary-layer growth.  The 
numerical simulations further showed that the pressure drop across the microneedle was 
minimized when its geometry was near that of a straight-sided cone.   
Agreement between our experimental data and numerical simulations is good (MAPE 
= 11%). The discrepancies are most probably the result of our idealization of microneedle 
geometry as a straight-sided cone. Due to the limitations of fabrication and measurement 
at the micron scale, actual microneedles did not always have perfectly circular cross 
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sections and needle diameters were estimated with an experimental uncertainty of 
approximately ± 3 µm (data not shown). Microneedles were not uniformly tapered either, 
often exhibiting a “Coke bottle” shape (Figure 3.1B). Although the simulations could 
account for some curvature in the needle taper, we did not simulate the complex 
curvature of these actual microneedles. As discussed above, such inaccuracies in the 
representation of the needle-tip geometry would then be a major factor contributing to the 
discrepancies between simulations and experiments.  Finally, microneedle walls had 
surface roughness features on the order of 0.1 µm (data not shown). Simulations assumed 
smooth walls.  
This study was motivated by applications in drug delivery and microfluidics.  The 
observation that tip geometry generally controls flow within tapered microneedles 
provides significant flexibility in needle design.  This is important when balancing design 
constraints to make needles that have the appropriate geometry and material properties to 
insert into skin without breaking or bending, avoid causing pain, and inject useful 
quantities of drug. We also observed that only kilopascal pressure drops were needed to 
flow many microliters per second through a micron-scale needle.  Battery-powered 
micropumps in a handheld or wearable device could easily apply such pressures and 
achieve flow rates of medical significance, especially if multi-needle arrays were used to 
increase throughput and add redundancy.  Not considered in this analysis is the resistance 
to fluid dispersion in the tissue into which a microneedle injection might be performed.  
Based on our preliminary measurements, this resistance can be considerable (data not 
shown) and, given the relatively low pressure drops across microneedles, tissue resistance 
is likely to be the dominant resistance to flow during a microneedle injection into skin.   
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4.1.6 Conclusions 
To develop microneedles for painless injection and other microfluidic applications, 
we experimentally determined the relationship between pressure drop and flow rate as a 
function of microneedle geometry and fluid viscosity. Pressure drops in the range of 4.6 – 
196.5 kPa were sufficient to flow liquids at rates of 1.4 – 56 µl/s, which suggests that 
micropumps could be used to deliver medically useful quantities of fluid from a patch-
like device. Numerical simulation showed that needle tip diameter and tip angle are the 
primary control parameters for flow through conically tapered microneedles, whereas 
other geometric features, such as needle length and inlet diameter, are much less 
important.  The curvature of the taper also plays a small role, with straight-sided needles 
exhibiting the least resistance to flow due to the nearly optimal development of the 
viscous boundary layers for this geometry and range of Reynolds numbers.  Altogether, 
the experimental and numerical results from this work suggest that a microneedle 
designed to deliver a maximum flow rate with minimum pressure drop would have the 
shape of a straight-sided cone with a cone half-angle of about 20 – 30º and a large tip 
diameter.  This work also shows that fluid can flow through microneedles for drug 
delivery and other microfluidic applications with only modest pressure drops that can be 
predicted and optimized using a numerical model.   
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4.2 Solid Microneedles for Transdermal Insulin Delivery6 
The purpose of this study were to design and fabricate arrays of solid microneedles 
and insert them into the skin of diabetic hairless rats for transdermal delivery of insulin to 
lower blood glucose level. Arrays containing 105 microneedles were laser-cut from 
stainless steel metal sheets and inserted into the skin of anesthetized hairless rats with 
streptozotocin-induced diabetes. During and after microneedle treatment, an insulin 
solution (100 or 500 U/ml) was placed in contact with the skin for 4 h. Microneedles 
were removed 10 s, 10 min or 4 h after initiating transdermal insulin delivery.  Blood 
glucose levels were measured electrochemically every 30 min. Plasma insulin 
concentration was determined by radioimmunoassay at the end of most experiments.   
As results, arrays of microneedles were fabricated and demonstrated to insert fully 
into hairless rat skin in vivo.  Microneedles increased skin permeability to insulin, which 
rapidly and steadily reduced blood glucose levels to an extent similar to 0.05 – 0.5 U 
insulin injected subcutaneously.  Plasma insulin concentrations were directly measured to 
be 0.5 – 7.4 ng/ml.  Higher donor solution insulin concentration, shorter insertion time, 
and fewer repeated insertions resulted in larger drops in blood glucose level and larger 
plasma insulin concentrations. In conclusions, Solid metal microneedles are capable of 
increasing transdermal insulin delivery and lowering blood glucose levels by as much as 
80% in diabetic hairless rats in vivo. 
 
                                                 
6 This work was published in Martanto, W., Davis, S. P., Holiday, N. R., Wang, J., Gill, H. S. and 




Previous work has demonstrated that microneedles are capable of piercing human 
skin (Davis, Landis, et al. 2004) and increasing skin permeability by orders of magnitude 
to small molecules (Henry, McAllister, et al. 1998) and proteins (McAllister, Wang, et al. 
2003) in vitro. Moreover, insertion of microneedles into human subjects is reported as 
painless (Kaushik, Hord, et al. 2001). Injection into chicken thigh in vitro using 
microneedles was shown by Stoeber and Liepmann (Stoeber and Liepmann 2000). Using 
hairless guinea pig skin in vivo, Lin et al. (Lin, Cormier, et al. 2001) studied the use of 
microneedles to deliver oligonucleotides with and without the addition of iontophoresis. 
Vaccine delivery has also received attention using antigen-coated microneedles, where 
Matriano et al. (Matriano, Cormier, et al. 2002) showed increased antibody titers to 
ovalbumin in hairless guinea pigs and Mikszta et al. (Mikszta, Alarcon, et al. 2002) 
demonstrated enhanced immune response to a DNA vaccine in mice.  
Building off these previous studies, we sought to investigate the use of microneedles 
to deliver a therapeutic protein and study the pharmacodynamic response in vivo. The 
specific aim of this study was to determine and study the effects of diffusion-based 
delivery of insulin to diabetic rats using solid microneedles. We therefore used 
microfabricated needle arrays to deliver insulin to diabetic hairless rats and measured 
insulin delivery and resulting changes in blood glucose levels. We selected insulin as a 
model drug because of its clinical relevance and great difficulty to deliver across intact 
skin (Owens 2002). Diabetes mellitus is one of the leading lethal diseases in the United 
States and worldwide, and is often treated by hypodermic injection of insulin.  Due to 
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patient discomfort that leads to poor patient compliance, alternative methods to 
administer insulin are of great interest.  
4.2.2 Fabrication and Characterization of Microneedles 
To develop a minimally invasive means to administer insulin across the skin and offer 
the possibility to continuously control the delivery rate, we designed and fabricated 
arrays of solid microneedles. These needles were made by laser-cutting needle structures 
from stainless steel sheets and bending the needles out of the sheet into an array 
containing 7 rows of 15 needles each, for a total of 105 needles. As shown in Figure 4.10, 
each needle measured 50 μm by 200 μm in width at the base, and tapered over a 1000-μm 




Figure 4.10 Scanning electron micrograph of solid metal microneedles shown next to the tip 
of a 27-gauge hypodermic needle. The complete microneedle array contains 105 needles, 
each measuring 1000 μm in length, 50 μm by 200 μm in cross section at the base, and 





The dark region visible behind each needle is the hole in the stainless steel sheet out of 
which each needle was bent.  Figure 4.10 also shows a 27-gauge hypodermic needle for 
size comparison. 
We used relatively long (i.e., 1 mm) microneedles in this study to facilitate easy 
insertion into the highly deformable skin of a rat, although shorter needles can also be 
inserted (Lin, Cormier, et al. 2001, Matriano, Cormier, et al. 2002, McAllister, Wang, et 
al. 2003). Even though human skin is thicker, still shorter needles may insert into human 
skin because it is less deformable on many parts of the body. On-going studies suggest 
that arrays of needles as large as 1 mm in length can be designed to avoid pain (data not 
shown).  
After making microneedles, we tested their ability to insert into hairless rat skin in 
vivo.  We found that insertion of this large array of needles by hand was difficult.  
However, with the aid of a high-velocity insertion device designed specifically for 
microneedle insertion, microneedles readily penetrated into the skin.  As shown in Figure 
4.11, microneedles were inserted to their full length into the skin, piercing across the 
epidermis and terminating within the dermis.  In Figure 4.11, the black material 
corresponds to the stainless steel needles, the lightly stained region adjacent to the needle 
array base is the epidermis, the darkly stained tissue below that is dermis, and the light 
tissue at the bottom of the image is subcutaneous tissue.    
Closer examination of Figure 4.11 indicates that some skin deformation occurred 
around each needle, as shown by the epidermal surface dimpled downward along the 
needle shaft (especially evident in the inset image).  Due to the angle of tissue sectioning, 
the left portion of the needle array has a continuous base, whereas the right portion shows 
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the holes in the base out of which each needle was bent.  To supplement the side view 
shown in the main image, the inset image displays a section rotated by 90º to show the 




Figure 4.11 Cross section of an array of microneedles inserted into rat skin in vivo and 
imaged by light microscopy after biopsy, fixation, and staining. The dark structures are the 
needles, which pierce vertically into the skin, and the base plate of the array, which is 
aligned horizontally along the skin surface. A portion of the base plate is missing on the 
right side, which corresponds to the hole in the base plate formed after cutting and bending 
the needle out at 90° (see text). The lightly stained tissue corresponds to the epidermis and 
the thicker, darkly stained tissue below corresponds to the dermis. The inset shows a side 
view of a single microneedle sectioned at an angle rotated 90° relative to the main image.  




To qualitatively assess the ability of microneedles to increase transdermal transport, a 
needle array was inserted and then removed from hairless rat skin in vivo, after which a 
dye solution was placed on the skin and then wiped off to stain the sites of needle 
penetration.  Figure 4.12 provides an image of the skin surface, which indicates that 
essentially all microneedles were inserted into the skin to create pathways for transdermal 
transport.    
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Figure 4.12 Surface of hairless rat skin after insertion and removal of microneedles in vivo 
followed by topical staining with a tissue-marking dye, as shown by light microscopy. Each 
stained spot corresponds to the site of microneedle penetration into the skin. 
 
 
4.2.3 Reduced Blood Glucose Levels 
We next tested the ability of microneedles to increase transdermal delivery of insulin 
to diabetic hairless rats. In these initial experiments, insulin was delivered for 4 h during 
and after a 10-min microneedle treatment. Then, insulin was removed from the skin and 
blood glucose levels were monitored for another 4 h. Figure 4.13 shows that blood 
glucose dropped rapidly and continuously during the 4-h insulin delivery period and 
eventually stabilized after insulin was removed (black symbols). In contrast, there was no 
significant drop in blood glucose levels in negative control rats (X symbols), in which 
insulin was applied to the rat’s skin without microneedles (ANOVA; p < 0.0001).  In 
comparison to positive control experiments using subcutaneous injection with a 
hypodermic needle (white symbols), changes in blood glucose level induced by 
microneedles were greater than those caused by injection of 0.05 U but less than 0.5 or 
1.5 U of insulin. This indicates that microneedles can increase skin permeability in a 
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long-lived manner to deliver physiologically relevant amounts of pharmacologically 





























Figure 4.13 Changes in blood glucose level in diabetic, hairless rats after insulin delivery 
using microneedles (▲), subcutaneous hypodermic injection of 0.05 U (◊), 0.5 U (□) or 1.5 U 
(○) of insulin, or passive delivery across untreated skin (×). Microneedles were inserted into 
skin for 10 min and then removed. Insulin solution was applied to the skin immediately 
after microneedle insertion and left on the skin for 4 h (as shown by arrow). Subcutaneous 
injections took a few seconds to perform. The pharmacodynamic effect of insulin delivery 
by microneedles was bounded by that of 0.05 – 0.5 U injected subcutaneously. Data are 
expressed as mean values (n ≥ 3) with average standard deviation associated with each data 





To further understand the effects of microneedles on transdermal insulin delivery, we 
examined the effect of delivery conditions on insulin delivery rate by varying three 
parameters: insulin concentration, needle insertion time, and number of insertions. Figure 
4.14 shows the effect of varying insulin donor solution concentration, where higher 
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insulin concentration (500 U/ml) reduced blood glucose levels to a greater extent than 
lower insulin concentration (100 U/ml) (ANOVA; p < 0.05), which is consistent with the 





























Figure 4.14 The effects of insulin donor concentration on changes in blood glucose level in 
diabetic, hairless rats. Higher insulin concentration (500 U/ml ( )) in the donor solution 
reduced blood glucose level to a greater extent than lower insulin concentration (100 U/ml 
( )) during delivery using microneedles that were inserted into skin for 10 min and then 
removed. Data are expressed as mean values (n ≥ 3) with average standard deviation 
associated with each data point of 15%. Blood glucose levels have been normalized relative 
to average pre-treatment levels. There was no significant drop in blood glucose levels in 
control rats exposed to insulin without microneedles (Figure 4.13). In all experiments, 




The effect of inserting microneedle arrays into the skin for different amounts of time 
is shown in Figure 4.15.  Microneedles inserted and then removed after just 10 s 
(followed by 4 h of insulin delivery across the skin) yielded larger drops in blood glucose 
level compared to that of removing the needles after 10 min, which in turn yielded larger 
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drops in blood glucose level compared to that of leaving the needles in the skin for the 
full 4 h (ANOVA; p < 0.0001). The observation that shorter insertion times are 
advantageous suggests applications might best involve a brief pretreatment with 





























Figure 4.15 The effects of needle insertion time on changes in blood glucose level in diabetic, 
hairless rats. To vary insertion time, microneedles were inserted into skin and then removed 
after 10 s ( ), 10 min ( ), or 4 h ( ).  Leaving needles inserted for longer times led to 
smaller reductions in blood glucose level. Data are expressed as mean values (n ≥ 3) with 
average standard deviation associated with each data point of 12%. Blood glucose levels 
have been normalized relative to average pre-treatment levels. There was no significant 
drop in blood glucose levels in control rats exposed to insulin without microneedles (Figure 
4.13). In all experiments, insulin remained in contact with the skin for 4 h (as shown by 




The reduced delivery caused at longer insertion times could be explained by the presence 
of needles blocking holes created in skin, by an unfavorable interaction (e.g., insulin 
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aggregation) between needles and insulin (McAllister, Wang, et al. 2003), or other 
effects.   
As shown in Figure 4.16, the number of needle insertions also affected blood glucose 





























Figure 4.16 The effects of number of insertions on changes in blood glucose level in diabetic, 
hairless rats. Microneedles were inserted into skin and then removed after 10 s for the 
single insertion experiment ( ), whereas microneedles were repeatedly inserted (for 10 s) 
and removed five times at the same site for the multiple insertion experiment (▲). Inserting 
the needles multiple times led to smaller reductions in blood glucose level. Data are 
expressed as mean values (n ≥ 3) with average standard deviation associated with each data 
point of 14%. Blood glucose levels have been normalized relative to average pre-treatment 
levels. There was no significant drop in blood glucose levels in control rats exposed to 
insulin without microneedles (Figure 4.13). In all experiments, insulin remained in contact 




glucose levels compared to that of a single insertion prior to insulin delivery (ANOVA; p 
< 0.001). The observation that repeated insertions resulted in smaller changes in blood 
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glucose level could be explained by local damage to the skin caused by multiple 
insertions that altered insulin clearance and capillary uptake in the skin.  Additional 
studies are needed to validate this hypothesis.   
4.2.4 Increased Plasma Insulin Concentration 
To supplement blood glucose measurements that indirectly assess the ability of 
microneedles to deliver insulin across skin, we directly measured plasma insulin 
concentration using a radioimmunoassay specific for the human insulin delivered (as 
opposed to endogenous rat insulin). Consistent with the observation that increased insulin 
concentration in the donor solution had a greater effect on blood glucose levels (Figure 





























Figure 4.17 Plasma insulin concentration in diabetic, hairless rats plotted versus donor 
solution insulin concentration. Plasma insulin levels increased with insulin concentration in 
the donor solution The experimental conditions were the same as in Figure 4.14. Blood 





The five-fold increase in donor insulin concentration resulted in approximately a ten–fold 
increase in plasma insulin concentration. This five-fold difference is within the 
experimental errors. Figure 4.18 shows that microneedle insertion time also influenced 
plasma insulin levels. Consistent with blood glucose measurements (Figure 4.15), shorter 




























Figure 4.18 Plasma insulin concentration in diabetic, hairless rats plotted versus 
microneedle insertion time. Plasma insulin levels decreased with longer microneedle 
insertion times. The experimental conditions were the same as in Figure 4.15. Blood samples 





The total insulin dose delivered can be estimated from these plasma insulin 
measurements. Given the low oil-solubility of insulin, we assumed that insulin non-
aqueous compartment volume of distribution is negligible (Kastin and Akerstrom 1999). 
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Based on an aqueous compartment volume of distribution in rats of 0.4 l/kg (Bachmann, 
Pardoe, et al. 1996, Sifton 2003), the total insulin dose delivered was 1.6 – 4.1 mU (0.06 
– 0.15 μg) using the 100 U/ml insulin formulation (Figure 4.18).  In contrast, Figure 4.13 
shows that microneedles lowered blood glucose levels to an extent bounded by 
subcutaneous injection of 0.05 – 0.5 U insulin.  This discrepancy could be explained by 
slower absorption or lower bioavailability of insulin injected subcutaneously compared to 
insulin delivered into the skin using microneedles.   
The results in Figure 4.13 – Figure 4.16 should be interpreted in the context of the 
effects of anesthesia on blood glucose level.  Urethane, which was used to anesthetize the 
rats, is well known to influence blood glucose levels in rodents (Sanchez-Pozo, Alados, et 
al. 1988).  Although glycemic levels are not altered in untreated diabetic rats, urethane is 
known to reduce the hypoglycemic effect of injected insulin by as much as 50% (Wang, 
Ren, et al. 2000).  This suggests that the blood glucose level reduction reported in this 
work may be similarly muted by the use of urethane. 
4.2.5 Implications for Transdermal Drug Delivery 
The ability of microneedles to create pathways across skin for delivery of insulin has 
potential significance for transdermal delivery of macromolecules. Using a relatively 
simple procedure, this study showed that microneedles are capable of delivering 
physiologically relevant amounts of biologically active insulin in vivo with no apparent 
lag time to onset of action. As a convenient and effective procedure, this study indicated 
that the skin could be briefly pretreated with microneedles and followed by application of 
a drug formulation to the treated site for many hours of transdermal delivery. When 
considered in combination with previous in vitro studies showing transdermal delivery of 
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compounds covering a broad range of molecular sizes (McAllister, Wang, et al. 2003) 
and in vivo studies showing delivery of oligonucleotides (Lin, Cormier, et al. 2001), as 
well as protein and DNA antigens (Lin, Cormier, et al. 2001, Matriano, Cormier, et al. 
2002), microneedles appear to be a broadly applicable technology for transdermal 
delivery.   
Of practical significance, microneedles can be fabricated using a number of different 
low-cost, mass-production technologies (McAllister, Wang, et al. 2003), including the 
laser-cutting approach used in this study. As a purely mechanical device that does not 
require electronic controls or a power supply, microneedles are expected to be less 
expensive, easier to use, and less likely to suffer from FDA-approval hurdles to validate 
manufacturing as compared to other approaches involving electrical, ultrasonic, thermal 
or other energy-based mechanisms.   
4.2.6 Conclusions 
Microfabricated arrays of solid metal microneedles were capable of fully inserting 
into the skin of hairless rats. These microneedles increased transdermal insulin delivery 
and thereby lowered blood glucose levels by as much as 80% in diabetic hairless rats in 
vivo. Shorter microneedle insertion times, fewer insertions, and larger insulin 
concentration in the donor solution all led to more insulin delivery and larger drops in 
blood glucose level. For the conditions used in this study, the pharmacodynamic response 
to insulin delivery using microneedles showed reduction in blood glucose levels similar 
to subcutaneous hypodermic injection of 0.05 – 0.5 U insulin. Direct measurements 
showed blood insulin concentrations of 0.5 – 7.4 ng/ml. Altogether, this study shows that 
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microneedles can be used to deliver biologically active protein in vivo, which suggests 
future uses for minimally invasive protein delivery in clinical applications. 
4.3 Hollow Microneedles for Transdermal Insulin Delivery7 
The goal of this study was to design, fabricate, and test arrays of hollow microneedles 
for minimally invasive and continuous delivery of insulin in vivo.  As a simple, robust 
fabrication method suitable for inexpensive mass production, we developed a modified-
LIGA process to micromachine molds out of polyethylene terephthalate using an 
ultraviolet laser, coated those molds with nickel by electrodeposition onto a sputter-
deposited seed layer, and released the resulting metal microneedle arrays by selectively 
etching the polymer mold. Mechanical testing showed that these microneedles were 
sufficiently strong to pierce living skin without breaking (data not shown in this thesis).  
Arrays containing 16 microneedles measuring 500 μm in length with a 75 μm tip 
diameter were then inserted into the skin of anesthetized, diabetic, hairless rats.  Insulin 
delivery through microneedles caused blood glucose levels to drop steadily to 47% of 
pre-treatment values over a 4-h insulin delivery period and were then approximately 
constant over a 4-h post-delivery monitoring period.  Direct measurement of plasma 
insulin levels showed a peak value of 0.43 ng/ml. Together, these data suggest that 
microneedles can be fabricated and used for in vivo insulin delivery.   
                                                 
7 This work was carried out in collaboration with Dr. Shawn Davis and was published in Davis, S. P., 
Martanto, W., Allen, M. G. and Prausnitz, M. R. Hollow metal microneedles for insulin delivery to diabetic 
rats. IEEE Trans Biomed Eng 52: 909-915 (2005). 
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4.3.1 Introduction 
To extend solid microneedles capabilities for transdermal insulin delivery, tapered 
hollow metal microneedles (Prausnitz 2004) were used to deliver insulin to diabetic rats 
in vivo. Hollow microneedles offer delivery pathways in which insulin can be transported 
into the skin via the needle lumen, which provides a transport pathway with a controlled 
geometry that facilitates controlled delivery into the skin. The specific aim of this study 
was to determine and study the effects of diffusion-based delivery of insulin to diabetic 
rats using hollow microneedles. 
4.3.2 Microneedle Design and Fabrication 
4.3.2.1 Microneedle Design 
Microneedles used for insulin delivery have a number of different design constraints: 
they must be strong enough to insert into skin without breaking, simple to fabricate and 
large enough to efficiently deliver clinically relevant amounts of insulin. Additional 
features such as lack of pain and biocompatibility were also taken into account. 
Microneedle insertion into skin depends on needle tip, length, spacing, wall thickness 
and needle material. Force of insertion into skin was shown to depend linearly on the 
interfacial area of the needle tip (Davis, Landis, et al. 2004) thus a needle with small tip 
diameter was preferable. Short and closely spaced needles cannot overcome the elastic 
deformation of skin and just dimple the skin without piercing.  Using similar high 
velocity insertion device for solid microneedle insertion, this limitation can be partially 
overcome (Rousche and Normann 1992). Therefore, an optimal needle spacing and 
length were selected based on these constraints. Wall thickness and needle material were 
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shown to affect fracture force of microneedle, thus a thin wall thickness and strong 
material were preferred. Fabrication process offered a constraint as well in which tapered 
mold is required to allow complete sputtering exposure for uniform electrodeposition. 
Taking into account all these constraints, hollow microneedles used for transdermal 
insulin delivery was made of nickel, 75 μm in outer tip diameter, 10 μm in wall 
thickness, an outer diameter of 300 μm at the needle base, taper angle of 12.7º relative to 
the central needle axis, 500 μm in length, had needle-to-needle spacing of 600 μm and 
inserted using a commercial device operating at approximately 10 m/s.  Although nickel 
does not pose significant safety concerns, it can cause skin irritation for individuals with 
nickel allergy (Hostýnek and Maibach 2002, Maibach and Menné 1989, Storrs, 
Rosenthal, et al. 1989). 
4.3.2.2 Microneedle Fabrication 
Microneedles with the geometry described above were fabricated using a process 
involving laser drilling a polymer mold, coating the mold with a conductive seed layer, 
electroplating the mold with metal, and finally releasing the resulting metal microneedle 
array by selectively wet etching the mold.  
Similar tapered needle molds used in fluid study experiments were laser-drilled by 
tracing the laser beam in a circular path whose diameter was less than the diameter of the 
circular beam. Electrodeposition onto these molds shown in Figure 3.1C yielded metal 
microneedles. An example of a hollow metal tapered microneedle is shown in Figure 
3.1B. Needle arrays of this geometry (shown in Figure 2.16) were used for the insulin 
delivery experiments described below.   
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4.3.3 Insulin Delivery 
To test the ability of microneedles to administer drugs, the arrays of hollow 
microneedles (Figure 2.16) were used to deliver insulin to diabetic rats.  Changes in 
blood glucose level and plasma insulin concentration were monitored during and after 
delivery of insulin through the microneedle arrays. 
Figure 4.19 shows the effect of microneedles on transdermal insulin delivery.  After 
application of the microneedle “patch” and an approximately 30 minute lag time, blood 
glucose level was steadily reduced over 4 h of insulin delivery to 47% of its original 
value (ANOVA, p < 0.001).  When insulin was subsequently removed from the skin, 
blood glucose level remained approximately constant during 4 h of post-delivery 
monitoring (ANOVA, p > 0.99). Animals receiving topical insulin without microneedles 
as a negative control did not show statistically significant changes in blood glucose level 
(ANOVA, p > 0.99).  This pharmacodynamic response was similar to that seen following 
subcutaneous hypodermic injection of 0.05 U of insulin and less than that seen for 
injection of 0.5 U of insulin, which were used as positive controls (positive controls are 






























Figure 4.19 Effects of transdermal insulin delivery using microneedles on blood glucose 
level in diabetic, hairless rats. Blood glucose level before, during, and after transdermal 
insulin delivery using microneedles inserted into the skin ( ) and through intact skin (×).  
The arrow indicates the beginning and end of the 4-h insulin delivery period. Data are 
expressed as mean values (n ≥ 3) with average standard deviation associated with each data 





 As a direct measure of insulin delivery, Figure 4.20 shows plasma insulin 
concentration as a function of time.  The radioimmunoassay used to determine insulin 
concentration was specific to the human insulin delivered, so that endogenous rat insulin 
was not detected.  Consistent with the blood glucose measurements, insulin was detected 
in plasma at the 30-min time point and at a higher concentration at the end of the 4-h 
delivery period.  Four hours after insulin was removed from the skin, plasma insulin 
levels did not change, which suggests slow release from a drug depot within the skin.  
Negative control experiments showed that topical insulin without microneedles produced 



























Figure 4.20 Plasma insulin concentration in diabetic, hairless rats during (0.5 and 4 h) and 
after (8 h) transdermal delivery using microneedles.  Data are expressed as mean values (n 
≥ 3) with average standard deviation associated with each data point of 16%. 
 
 
4.3.4 Interpretation of Insulin Delivery Results 
We refer to the microneedle device as a “patch” because its operation is similar to a 
transdermal patch.  Microneedles were used to pierce across the skin’s outer barrier layer, 
stratum corneum, and provide conduits for insulin transport into the skin for capillary 
absorption and systemic distribution.  Insulin delivery was by diffusion over time from a 
reservoir on the skin surface. Although not done in this study, microneedles can also be 
used in a manner more like an injection, where a drug solution is actively flowed through 
the needles and into the skin (McAllister, Wang, et al. 2003). 
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The results in Figure 4.19 should be interpreted in the context of the effects of 
anesthesia on blood glucose level.  Urethane, which was used to anesthetize the rats, is 
well known to influence blood glucose levels in rodents (Sanchez-Pozo, Alados, et al. 
1988).  Although glycemic levels are not altered in untreated diabetic rats, urethane is 
known to reduce the hypoglycemic effect of injected insulin by as much as 50% (Wang, 
Ren, et al. 2000).  This suggests that the blood glucose level reduction reported in this 
work may be similarly muted by the use of urethane. 
Given the low oil-solubility of insulin, we used the assumption that insulin non-
aqueous compartment volume of distribution is negligible (Kastin and Akerstrom 1999). 
Blood glucose pharmacodynamic measurements (Figure 4.19) suggest that on the order 
of 50 mU of insulin was delivered by microneedles. In contrast, direct pharmacokinetic 
measurements (Figure 4.20) demonstrating 0.43 ng/ml (12 μU/ml) of plasma insulin 
corresponds to a dose of 1.4 mU, based on a 0.4 l/kg volume of distribution (Bachmann, 
Pardoe, et al. 1996, Sifton 2003).  This order-of-magnitude difference may be explained 
by slower absorption of insulin injected into the subcutaneous space compared to delivery 
near the capillary loops at the dermal-epidermal junction using microneedles. 
4.3.5 Conclusions 
To provide arrays of hollow metal microneedles that could be mass produced for 
minimally invasive drug delivery, we developed a fabrication method to laser-drill a 
polymer mold, coat the mold with a conductive seed layer, electroplate the mold with 
metal, and release the metal microneedles by selectively etching the mold. Using this 
approach, combined with a laser-trepanning technique to produce tapered holes, 
microneedles were fabricated with a wide range of different geometries. The needle 
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geometry selected for detailed study was shown to insert into skin of human subjects 
without breaking. Drug delivery experiments using an 16-microneedle array inserted into 
the skin of diabetic, hairless rats showed that insulin was delivered into the bloodstream 
and that the blood glucose level was reduced by 47% over a 4-h insulin delivery period.  
Overall, these results suggest that microneedles can be fabricated for minimally invasive 
delivery of insulin, or other compounds, for continuous or possibly modulated 
administration over time.   
4.4 Microinfusion Using Hollow Microneedles 
The purpose of this study was to determine the effect of experimental parameters on 
microinfusion through hollow microneedles into skin to optimize drug delivery protocols 
and identify rate-limiting barriers to flow. Glass microneedles with tip radii of 22–48 μm 
and bevel angles of 35-38º were fabricated using a micropipette puller and inserted to a 
depth of 720-1080 μm into human cadaver skin to microinfuse sulforhodamine solution 
at constant pressure. Flow rate was determined as a function of experimental parameters, 
such as microneedle tip geometry, insertion and retraction distance, infusion pressure, 
presence of hyaluronidase, and time. 
Single microneedles infused sulforhodamine solution into skin at flow rates ranging 
from 21 to 1130 μl/h. Infusion flow rate through microneedles was increased by greater 
insertion depth, larger retraction distance, larger infusion pressure, use of a beveled 
microneedle tip, and the presence of hyaluronidase. These effects can be explained by 
removing or overcoming the large flow resistance imposed by dense dermal tissue 
blocking flow from the needle tip. By understanding the barriers to fluid flow into skin, 
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protocols can be designed for hollow microneedles to microinfuse fluid at therapeutically 
relevant rates. 
4.4.1 Introduction 
Infusion pumps are used for many clinical applications, including intravenous, 
epidural, and subcutaneous delivery of analgesics and anesthetics, antibiotics, 
cardiovascular drugs, and insulin (Bode, Sabbah, et al. 2002, Doyle, Weinzimer, et al. 
2004, Findley and Chamberlain 1999, Fox and Rowbotham 1999, Herndon and Fike 
2001, Lenhard and Reeves 2001, Moulin and Kreeft 1991, Pasero 2002, Pickup, Mattock, 
et al. 2002). Drug delivery via infusion reduces the plasma drug concentration fluctuation 
associated with oral delivery and the slow onset and long depot effect associated with 
transdermal patch delivery. Infusion pumps are commonly used when continuous, 
intermittent or pulsatile delivery of drug is needed. They also provide an alternative for 
patients intolerant to oral administration and can be programmed to achieve special 
delivery profiles. The use of infusion pumps outside the clinical setting has been limited 
by the device’s bulky size and expensive cost (Colquitt, Green, et al. 2004) as well as its 
low patient compliance due to the inconvenience of an indwelling catheter that has a 
relatively large infusion set and the expertise required to properly use it (Liebl 2002, 
Moulin and Kreeft 1991) 
Recently, a compact, disposable drug delivery device that incorporates a relatively 
short, 5-mm long hypodermic needle has been shown to continuously and subcutaneously 
infuse drug solutions, such as heparin to prevent thrombosis (Meehan, Gross, et al. 1997) 
and morphine sulfate for management of cancer pain (Gross and Kelly 1996, Gross, Lavi, 
et al. 2002, Gross, Tsals, et al. 2003, Lynch, Butler, et al. 2000, Meehan, Gross, et al. 
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1997). This type of device can be worn on the skin in a discrete and convenient manner 
and deliver drug from a pressure-driven reservoir through the needle into the skin. 
Despite its minimally invasive approach, local erythema, edema, and contact dermatitis at 
the injection site have been reported with the use of this device (Jolanki, Kanerva, et al. 
2001). As a further improvement, needles could be made still smaller to provide an even 
less invasive and painless needle to increase patient compliance.   
To address this need, we and others have adapted microfabrication technology to 
produce needles of micron dimensions. Microneedles can be coupled with a micropump 
to make a wearable infusion device that is highly patient friendly and can serve as a 
potential replacement for conventional hypodermic needles and infusion sets. 
Microneedles are expected to be safe, because they are minimally invasive devices that 
are inserted only into skin’s superficial layers and are typically bloodless and painless. 
Microneedles are also expected to be effective, as a hybrid between transdermal patches 
and injection/infusion.  
Microneedles were originally designed to increase skin permeability for patch-based 
delivery by diffusion. In this application, solid microneedles have been shown to increase 
transdermal transport by orders of magnitude in vitro for a variety of compounds (Chabri, 
Bouris, et al. 2004, McAllister 2000). In vivo studies have demonstrated delivery of 
insulin (Davis, Martanto, et al. 2005), oligonucleotides (Lin, Cormier, et al. 2001), human 
growth hormone (Cormier and Daddona 2003), and desmopressin (Cormier, Johnson, et 
al. 2004), as well as ovalbumin (Matriano, Cormier, et al. 2002), DNA (Mikszta, 
Alarcon, et al. 2002) and anthrax (Mikszta, Sullivan, et al. 2005) vaccines.  Human pain 
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studies have shown that insertion of microneedles can be painless and does not cause skin 
irritation (Kaushik, Hord, et al. 2001, Mikszta, Alarcon, et al. 2002)  
Of greater relevance to infusion, microneedles containing a hollow bore have also 
been made using a variety of different microfabrication approaches (McAllister, Allen, et 
al. 2000, Reed and Lye 2004). Active injection using hollow microneedles coupled to a 
syringe or pump has been demonstrated for insulin delivery to diabetic hairless rats in 
vivo (Gardeniers, Luttge, et al. 2003, McAllister, Wang, et al. 2003), administration of 
chemical stimuli into brain tissue in vivo (Chen, Wise, et al. 1997), and injection of 
fluorescent dye into chicken thigh in vitro (Stoeber and Liepmann 2002). Hollow 
microneedles have also been used to passively deliver insulin by diffusion to diabetic rats 
(Davis, Martanto, et al. 2005) and to extract nanoliter quantities of blood for glucose 
measurement in human (Smart and Subramanian 2000).   
Motivated by these studies demonstrating microinjection of drugs into skin using 
hollow microneedles, there is a need for systematic study of the effects of infusion 
parameters, and their optimization, on flow rate using hollow microneedles. Previous 
studies in the literature report delivery of relatively small volumes of drug solution into 
the skin, which were enough to have effects on rodents, but may not be sufficient to 
accommodate many human doses. To address the need to increase and control infusion 
rate, this study sought to experimentally quantify the relationship between infusion flow 
rate and different experimental parameters, such as needle insertion depth, retraction 
distance, infusion pressure, needle geometry, and the presence of hyaluronidase. We 
therefore used single glass microneedles to infuse sulforhodamine solution into human 
cadaver skin and measured the infusion flow rate as a function of various experimental 
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parameters. The resulting data were used to determine optimal infusion protocols and 
identify rate-limiting barriers to flow. Analysis was guided by the hypothesis that 
infusion through hollow microneedles into skin is limited by the resistance to flow 
offered by dense dermal tissue compressed during microneedle insertion. 
4.4.2 Fabrication and Characterization of Microneedles 
Although clinical applications of microneedles are envisioned using multi-needle 
arrays made of metal that are mass-produced by microfabrication, we used hand-drawn 
glass microneedles in this study to facilitate easy visualization of microinfusion into the 
skin and because of their versatility to be rapidly fabricated in various geometries. A 
representative glass microneedle is shown in Figure 4.21. These needles could be 

















Figure 4.21 (A) Front and (B) side views of a representative hollow, glass microneedle. The 




Single microneedles were inserted into human cadaver skin in vitro to a controlled 
depth and then, sometimes, partially retracted. Figure 4.22 shows a cross section of a 
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piece of skin pierced with a microneedle and then chemically fixed for histological 
sectioning and staining. The hole made by the microneedle is evident, measuring 300 –
350 μm deep and having the same shape as the microneedle.  Some deformation of the 
skin surface is also evident, due to skin deflection during insertion. A small volume of 
dye was injected into the skin and its infusion trajectory is also shown in Figure 4.22. 
More dye is present on the right side of the image, presumably because the needle bevel 
was on the right and channeled flow in that direction. The directional nature of the flow 
further appears to be influenced by skin microstructure, where infusion pathways follow 
dermal collagen fiber orientation. As a comparison, Figure 4.23 shows a cross section of 





Figure 4.22 Histological section of human cadaver skin pierced with a hollow microneedle 
in vitro. The needle was inserted to a depth of 1080 μm and then retracted 720 μm to a final 
insertion depth of 360 μm. The needle had a 36º beveled tip with a 32 μm effective radius 
opening. A small amount of blue dye was infused into the skin at a pressure of 138 kPa for 1 
min and then the skin was fixed with the needle in place.  Before H&E staining and 
histological sectioning, the needle was removed and is not present in the image shown. The 
site of needle insertion is evident as the triangular region missing tissue and the paths of 









In a typical experiment, hundreds of microliters of fluid were infused into skin, which 
was distributed over an area measuring millimeters to centimeters across. Figure 4.24 
shows representative images of the top and bottom surfaces of human cadaver skin after 
sulforhodamine infusion using a microneedle. All dye was contained within the skin and 
did not represent surface staining; leakage onto the skin surface during infusion was 
rarely seen. Dye distribution observed from the skin surface, shown as the circular dark 
area in Figure 4.24A, was generally more constrained than when viewed from underneath 
the skin, as shown by the widespread staining in Figure 4.24B. Additional studies showed 
that microneedles could also be inserted into pig and rat cadaver skin to microinfuse 
















Figure 4.24 (A) Top and (B) bottom surfaces of human cadaver skin after infusion of 
sulforhodamine solution using a hollow microneedle in vitro. Sites of sulforhodamine 
infusion are indicated by dark red staining. Infusion of 755 μl of solution was carried out 
over 104 min at 138 kPa using a microneedle with a 31 μm effective radius opening and a 
bevel angle of 37º inserted to a depth of 1080 μm into the skin and retracted 720 μm to a 










4.4.3 Effect of Insertion and Retraction 
To determine the effects of infusion parameters, microneedle infusion flow rates were 
measured over a range of different experimental conditions. Considering the most 
straightforward scenario of microneedle insertion without retraction, microneedle 
insertion to a depth of 1080 μm permitted sulforhodamine solution flow into the skin at a 
rate of 28 μl/h (Figure 4.25A). Retraction of the needle led to progressively larger flow 
rates, where a 900 μm retraction, corresponding to a net insertion of 180 μm, produced a 
flow rate of 326 μl/h. Initial insertion to lesser depths similarly produced low flow rates 
that were progressively increased with needle retraction (Figure 4.25B and Figure 4.25C). 
When these data from different insertion and retraction combinations are combined, a 
significant increase in flow rate with increasing retraction distance is apparent (Figure 
4.25D; ANOVA, p < 0.05). Further analysis also shows a significant increase in flow rate 
with increasing initial insertion depth (ANOVA; p < 0.001). Decreasing the net insertion 
depth, which corresponds to the initial insertion depth minus the retraction distance, also 
resulted in a larger flow rate (Figure 4.25E; ANOVA, p < 0.05).  
Considered together, these findings demonstrate that flow rate is largest when 
retraction distance is maximized by inserting deeply and retracting almost completely. 
This is consistent with our hypothesis that compressed dermal tissue blocks flow from 
microneedles, since needle retraction should relieve compressive forces applied to the 
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Figure 4.25 Effect of insertion depth and retraction distance on flow rate into human 
cadaver skin in vitro. Microneedles were initially inserted to a maximum insertion depth of 
(A) 1080 μm, (B) 900 μm or (C) 720 μm and then retracted various distances back toward 
the skin surface to a final, net insertion depth. Pooling the data from parts (A), (B), and (C), 
flow rate is shown as a function of (D) retraction distance and (E) net insertion depth for 
maximum insertion depths of 720 μm (white bars), 900 μm (striped bars) and 1080 μm 
(black bars). Microneedles had tip opening effective radii of 27 – 31 μm with bevel angles of 
35 – 37º. Infusion was performed for 5 min at 138 kPa without needle retraction, after 
which, microneedles were retracted by 180 μm every 5 min to a final insertion depth of 180 
μm. Data are expressed as mean values (n ≥ 3) with standard deviation bars. 
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The observed increase in infusion flow rate as a result of increasing retraction 
distance can be better understood by examining the interstitial components of dermal 
tissue. Skin can be modeled as a porous viscoelastic material which is composed of a 
continuous fluid phase (i.e., mostly water) within a network of coarse, fixed elements of 
collagen fibrils and elastin and a meshwork of finer fibers composed of 
glycosaminoglycan (GAG) and proteoglycan immobilized by the collagen (Hay 1981, 
Levick 1987, Meyer, Laver-Rudich, et al. 1983). Fixed fibrous obstacles spanning the 
intercellular spaces within dermis offer high resistance to fluid flow. Resistance to flow 
within dermal tissue arises as a result of the combined interactive resistances offered by 
three main classes of fibrous elements: collagen fibrils, (GAG), and proteoglycan core 
protein (PGP).  
Collagen fibrils (~ 20 nm radii) occupy a substantial dermal tissue volume, given 
their fractional volume of 0.66. Collagen fibrils reduce fluid hydraulic conductivity by 
reduction of area for flow and increased tortuosity. Collagen fibrils increase the flow path 
length by imposing a tortuous pathway (i.e., with a tortuosity factor of 0.7) (Sullivan and 
Hertel 1942). The relatively large surface area of collagen also increases hydraulic 
resistance due to viscous interaction with the flowing fluid. The presence of GAG (~ 0.5 
nm radii) also increases the hydraulic resistance within the dermis, as shown by the 
significant increase in flow rate after GAG removal using hyaluronidase (Figure 4.29). 
Previous studies (Levick 1987) also indicated that non-collagen fibrous proteins, of 
which the most abundant is PGP (~ 1 nm radii), also play a significant role in 
determining hydraulic flow resistance.  
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The framework of collagen and proteoglycan is usually assumed to be fixed relative 
to the fluid, i.e., proteoglycan does not flow with the fluid. Given the relatively small 
sizes of fibrous components within the dermis, compression caused by microneedle 
insertion can reduce the inter-fiber spacing interstitium components. This will increase 
the hydraulic resistance to flow. Preliminary data shows that microneedle insertion 
induces a compressive force of approximately 1.4 N to the dermal tissue (data not 
shown). Compression of tissue is known to reduce tissue hydration (Levick 1987). 
Hydraulic resistance is also known to increase with decreasing tissue hydration (Bert and 
Reed 1995). Thus, by retracting microneedles after insertion into skin, flow hydraulic 
conductivity within dermal tissue is expected to increase due to the release of 
compressive forces on the tissue, expansion of dense dermal tissue and increase in dermal 
tissue hydration. 
4.4.4 Effect of Infusion Pressure 
Infusion pressure is expected to affect flow rate, and, as shown in Figure 4.26, flow 
rate increased with increasing pressure (ANOVA, p < 0.0001). Increased infusion 
pressure certainly increased flow rate by increasing the pressure-driven driving force for 
flow, but might also act by displacing or deforming tissue to reduce resistance to flow. To 
decouple these two effects, we expect that flow rate should increase in direct proportion 
to pressure if pressure acts only as a driving force for convection (Fox and McDonald 
1998). In contrast, pressure-mediated changes in skin microstructure that reduce flow 
resistance are expected to have a nonlinear dependence on pressure (McGuire and Yuan 






















Figure 4.26 Effect of pressure on flow rate into human cadaver skin. Microinfusion flow 
rate was measured as a function of retraction distance at three pressures: 69 kPa (white 
bars), 138 kPa (striped bars) and 172 kPa (black bars). Microneedles having 35 – 37º 
beveled tips with 27 – 32 μm effective radius openings were inserted to a maximum depth of 




Guided by these expected behaviors, the flow rate data shown in Figure 4.26 were 
normalized by the infusion pressure. From 69 to 138 kPa, the increase in flow rate was 
proportional to the increase in pressure (ANOVA, p = 0.14). However, at 172 kPa, the 
flow rate showed a disproportionately large increase relative to the pressure increase 
(ANOVA, p < 0.001). This nonlinearity suggests that elevated pressure reduced flow 
resistance by displacing or deforming the dense dermal tissue impeding flow. 
4.4.5 Effect of Microneedle Tip Bevel 
Dermal tissue compressed by needle insertion should be most dense at the needle tip. 
Thus, flow from a blunt-tip microneedle, where the hole is located at the needle tip, 
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should encounter greater resistance than flow from a bevel-tip microneedle, where the 
hole is off to the side. Consistent with this hypothesis, infusion flow rate from a bevel-tip 
microneedle was on average 3-fold greater than from a blunt-tip microneedle (Figure 




























Figure 4.27 Effect of tip bevel on flow rate into human cadaver skin. Microinfusion flow 
rate was measured as a function of retraction distance during infusion using hollow 
microneedles with a blunt tip (white bars; left inset image) and a 35º beveled tip (black 
bars; right inset image). Microneedles with 27 – 32 μm effective radius openings were 
inserted to a maximum depth of 1080 μm and infusion was carried out at 138 kPa. Data are 
expressed as mean values (n ≥ 3) with standard deviation bars.  
 
 
4.4.6 Effect of Microneedle Tip Opening Size 
If dense dermal tissue is the main barrier to flow, the size of the microneedle tip 
opening is expected to have only small effects since the microneedle itself does not 
impose the rate-limiting barrier. Consistent with this expectation, varying tip openings 
with effective radii ranging from 22 to 48 μm (i.e., tip areas ranging from 1462 to 7400 
 116
μm2) had no significant effect on infusion flow rate (Figure 4.28; ANOVA, p = 0.27). 
This suggests that the primary resistance to flow is not at the needle tip–to–skin interface, 
which would be heavily influenced by a 5-fold change in area. Instead, the volume of 
dense dermal tissue surrounding the tip appears to limit flow, where the size and density 
of this tissue is probably governed primarily by the depth of needle insertion and 





























Figure 4.28 Effect of tip opening size on flow rate into human cadaver skin. Microinfusion 
flow rate was measured as a function of retraction distance using three different tip opening 
sizes: 22 μm (black bars; left inset image), 30 μm (striped bars; center inset image) and 48 
μm (white bars; right inset image) effective radii. Microneedles having 35 – 37º beveled tips 
were inserted to a maximum depth of 1080 μm and infusion was carried out at 138 kPa. 
Data are expressed as mean values (n ≥ 3) with standard deviation bars. 
 
 
4.4.7 Effect of Hyaluronidase 
Hyaluronidase is known to reduce flow resistance in the skin by breaking down 
hyaluronan, a glycosaminoglycan within skin collagen fibers (Bruera, Neumann, et al. 
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1999, Kreil 1995, Meyer 1971).  This enzyme might similarly break down the resistance 
of dermal tissue compressed during microneedle insertion. To test this prediction, 
microneedle infusion was carried out using our standard sulforhodamine solution mixed 
with a purified ovine testicular hyaluronidase preparation (Vitrase®) that is commercially 
available and FDA approved for human use (2003). Addition of hyaluronidase increased 






















Figure 4.29 Effect of hyaluronidase on flow rate into human cadaver skin. Microinfusion 
flow rate was measured as a function of retraction distance during infusion in the absence 
(white bars) or presence (black bars) of hyaluronidase. Microneedles having 35 – 37º 
beveled tips with 27 – 32 μm effective radius openings were inserted to a maximum depth of 
1080 μm and infusion was carried out at 138 kPa. Data are expressed as mean values (n ≥ 3) 




This finding further supports the global hypothesis that dense dermal tissue limits flow 
from microneedles. It also suggests applications, where hyaluronidase or other 
compounds that affect skin microstructure could be co-administered to facilitate infusion 
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using microneedles. Potential interaction between hyaluronidase and infused therapeutic 
protein or drugs was not considered in this study. 
4.4.8 Microinfusion Over Time 
In other scenarios, the resistance to fluid flow into tumor tissue at constant pressure 
has been shown to decrease over time, probably due to flow-induced changes in tissue 
microstructure (McGuire and Yuan 2001, Zhang, Luck, et al. 2000). To address this 
possibility during infusion using microneedles, we measured sulforhodamine flow into 
skin continuously for 104 min for needles inserted and left in place and for needles 


























Figure 4.30 Cumulative infusion volume during infusion into human cadaver skin over time 
for microneedles inserted into skin to a depth of 1080 μm and then retracted 720 μm to a 
final insertion depth of 360 μm (solid line) and microneedles inserted to a depth of 1080 μm 
without retraction (dashed line). Infusion was carried out at 138 kPa using microneedles 
having 35 – 38º beveled tips with 30 – 32 μm effective radius openings. Data are expressed 






















In both cases, the cumulative volume of fluid infused into skin increased linearly with 
time (linear regression correlation coefficient, R2 > 0.99), suggesting that skin resistance 
to flow did not change over the timescale studied. Note that the pressure used in this 
experiment was less than the pressure identified previously to induce non-linear changes 
in flow rate (Figure 4.26), which is consistent with this observation that flow rate did not 
change with time. Despite the generally linear trend, the flow rate was transiently higher 
at the onset of flow and then decayed within a few minutes to a steady state (Figure 4.30 
inset). This effect might be explained by the rapid filling of a small cavity in the skin at 
the needle tip formed by the insertion/retraction process, followed by slower infusion into 
and across intact, compressed tissue. 
Given the relatively low pressure drop across the microneedles, tissue resistance is 
expected to be the dominant resistance to flow during a microneedle injection into skin. 
To test this hypothesis, flow rate measurement from Figure 4.1, which corresponds to 
flow of fluid through microneedles into the air (i.e., without the presence of skin for 
microneedles with radii of 25 and 34 μm), was plotted together with a subset of flow rate 
measurements in Figure 4.26, which correspond to flow of fluid through microneedles 
during microinfusion into skin (i.e., at infusion pressures of 69, 138, 172 kPa with and 
without the presence of hyaluronidase). This comparison is shown in Figure 4.31, which 
indicates that the presence of skin tissue decreases the flow rate by one or more orders of 
magnitude. Overall this result suggests that dermal tissue offers significant resistance to 























Figure 4.31 Effect of skin on flow rate through microneedles. Fluid flow rate was measured 
as a function of pressure across microneedles with (filled symbols) and without (empty 
symbols) the presence of skin. Fluid flow rates through microneedles with (ο) 25 μm and (□) 
34 μm radii (data from Figure 4.1) were compared to those with the skin present, in which 
microinfusion into skin using microneedles was performed with insertion depth of 1080 μm 
without retraction ( ), with insertion depth of 1080 μm and retracted 540 μm without the 
presence of hyaluronidase (▲) and with the presence of hyaluronidase ( ) (data from 
Figure 4.26 and Figure 4.29). Data are expressed as mean values (n ≥ 3) with standard 
deviation bars.   
 
 
4.4.9 Implications for Transdermal Drug Delivery 
This study suggests that microneedles can infuse fluid into skin over a range of flow 
rates that can be controlled by various infusion parameters. Flow rate was maximized by 
infusing at high pressure with hyaluronidase through beveled needles inserted deeply and 
retracted almost completely. These effects can be explained by the overall hypothesis that 
infusion through hollow microneedles into skin is limited by the resistance to flow 
offered by dense dermal tissue compressed during microneedle insertion. Needle 
retraction increases flow rate by relieving compressive forces applied to the tissue by the 
 121
microneedle and allowing compressed tissue to expand. Increased pressure also increases 
flow rate by increasing the driving force and by displacing or deforming tissue to reduce 
resistance to flow. A beveled microneedle reduces flow resistance by infusing to the side 
of the dense tissue formed at the needle tip. Hyaluronidase attacks glycosaminoglycan 
structure within skin to break down the barriers to flow. Needle tip opening size did not 
affect infusion, because the compression of tissue at the needle tip is governed primarily 
by the depth of needle insertion and retraction.  
The study is significant because it is the first to systematically examine the effects of 
infusion parameters and optimize them to increase flow rate into skin using hollow 
microneedles. In contrast to previous studies that infused relatively small volumes using 
non-optimized protocols, this study provides strategies to increase flow rate using 
appropriate insertion protocols and needle design. In addition to these experimental 
observations, the mechanistic interpretation that compressed tissue is a rate-limiting 
barrier to flow provides a rational approach to further optimize infusion methods and 
design new approaches.   
Single microneedles can infuse fluid into skin at flow rates up to 1 ml/h, which is 
sufficient for many applications. Delivery from an array containing multiple needles 
should increase flow rates further, possibly increasing linearly with the number of 
needles. In this way, hollow microneedles can be envisioned as a minimally invasive 
alternative to conventional infusion sets based on hypodermic needles and catheters. In 
one scenario, microneedles could be coupled with a commercially-available infusion 
pump to provide a patient-friendly needle alternative that could be especially attractive 
for home use by patients. Due to their low profile, microneedles could also be mounted 
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on the base of a small, “wearable” pump that could be applied to the skin much like an 
oversized patch for still greater patient convenience. Potential applications of this 
technology include insulin, hormonal therapies requiring pulsatile delivery, and drugs 
with short half lives that require frequency administration.    
Despite these opportunities, there are limitations to infusion using microneedles. The 
maximum flow rate observed in this study is much slower than hypodermic injection, 
suggesting that microneedles are not appropriate when rapid bolus delivery is needed, for 
example, in emergency situations. Moreover, some infusion protocols require intravenous 
administration, which microneedles cannot achieve, inherent to their design. Although 
average flow rate over extended time was stable for 104 min in this study, instantaneous 
flow rate showed some instability using a constant pressure driving force (e.g., Figure 
4.30). This problem could be addressed by using a constant flow rate pump instead. 
Finally, cost-effective applications will require replacing the single, hand-drawn, glass 
needles used in this study with arrays of metal microneedles mass-produced by adapting 
existing microfabrication technology and integrating them into user-friendly devices 
containing a drug reservoir, micropump, and microelectronic controls. 
4.4.10 Conclusions 
Guided by the hypothesis that infusion through hollow microneedles into skin is 
limited by the resistance to flow offered by dense dermal tissue compressed during 
microneedle insertion, this study systematically examined the effects of infusion 
parameters and optimized them to increase flow rate into skin. Overall, flow rate was 
optimized by inserting needles deeply and then retracting almost completely, infusing at 
high pressure, using microneedles with a beveled tip, and adding hyaluronidase to the 
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infusion fluid. Microneedle tip opening size did not significantly affect flow rate. 
Infusion over longer times demonstrated a constant flow rate after a short, transient burst 
at constant pressure. Altogether, this study shows that hollow microneedles can be 
designed to infuse milliliter quantities of fluid into skin to make transdermal delivery of 
many drugs possible and to provide a minimally invasive alternative to conventional 





















Transdermal drug delivery offers a less invasive way to deliver drug across the skin 
compared to painful injection using hypodermic needles. In addition, it also overcomes 
problems with oral delivery such as poor absorption and enzymatic degradation of drugs. 
Despite these advantages, passive transdermal drug delivery using patches is limited to a 
dozen FDA-approved drugs which have certain desired transport properties across the 
skin. Microneedles were previously fabricated to address the problems associated with 
hypodermic injection, transdermal patches and oral delivery. 
To develop an optimized design of microneedles for painless injection and other 
microfluidic applications, in this study, we used hollow microneedles to determine the 
relationship between pressure drop and flow rate as a function of microneedle geometry 
and fluid viscosity. Hollow microneedles can be used to flow liquids at rates of 1.4 – 56 
µl/s with pressure drops in the range of 4.6 – 196.5 kPa, which suggests that 
microneedles could be coupled with micropumps to deliver therapeutically useful 
quantities of fluid from a patch-like device. Needle tip diameter and tip angle are the 
primary control parameters for flow through conically tapered microneedles, whereas 
other geometric features, such as needle length and inlet diameter, are much less 
important as shown by numerical simulation. The curvature of the taper also plays a 
small role, with straight-sided needles exhibiting the least resistance to flow due to the 
nearly optimal development of the viscous boundary layers for this geometry and range 
of Reynolds numbers. This study suggests that a maximum flow rate and minimum 
pressure drop can be achieved using microneedles with a straight-sided cone, a cone half-
angle of about 20 – 30º and a large tip diameter. This work also shows that microneedles 
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can be used to flow fluid for drug delivery and other microfluidic applications with only 
modest pressure drops that can be predicted and optimized using a numerical model. This 
study provided the first detailed study of flow through microneedles specifically and of 
developing flow through conical channels in general. Given the relatively low pressure 
drops across microneedles, tissue resistance is likely to be the dominant resistance to flow 
during a microneedle injection into skin.   
In this study, we also demonstrated the use of solid metal microneedle arrays to insert 
into the skin of hairless rats to increase transdermal insulin delivery and thereby lower 
blood glucose levels by as much as 80% in diabetic hairless rats in vivo. More insulin 
delivery and larger drops in blood glucose level were achieved by shorter microneedle 
insertion times, fewer repeated insertions and larger insulin concentration in the donor 
solution. Microneedle-based insulin delivery showed reduction in blood glucose levels 
similar to subcutaneous hypodermic injection of 0.05 – 0.5 U insulin. Direct 
measurements showed blood insulin concentrations of 0.5 – 7.4 ng/ml. Solid 
microneedles were capable to fully insert into skin and deliver insulin due to their 
relatively long length (i.e., 1 mm) and sharp tips which facilitate easy insertion with 
minimal skin deformation. Altogether, this study demonstrated, for the first time, that 
microneedles can be used to deliver a biologically active, therapeutic protein in vivo, 
which suggests future uses for minimally invasive protein delivery in clinical 
applications. 
To extend microneedle delivery capabilities, we used hollow tapered microneedles to 
insert into the skin of diabetic, hairless rats and deliver insulin that resulted in blood 
glucose level reduction by 47% over a 4-h insulin delivery period.  Given that the tips of 
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hollow microneedles were not as sharp as those in solid microneedles, greater skin 
deflection was encountered during their insertion into skin when compared to that of 
solid microneedle insertion. Despite significant skin deflection, the tips of hollow 
microneedles were capable to create transport pathways across the stratum corneum to 
allow insulin diffusion. This study represented the first demonstration of diffusion-based 
delivery through hollow microneedles. Overall, these results suggest that solid and 
hollow microneedles can be fabricated for minimally invasive delivery of insulin, or 
other compounds, for continuous or possibly modulated administration over time. 
To further optimize the design and use of hollow microneedles for microinfusion, we 
determined the effect of microneedle geometry and various infusion parameters on 
infusion flow rate using glass microneedle injections into skin. Larger infusion flow rate 
could be achieved by a microneedle with beveled tip which was inserted deeper into the 
skin. In addition, larger infusion pressure and the presence of hyaluronidase led to a 
larger infusion flow rate as well. Increased flow rate during infusion using bevel tip 
microneedles could be explained as a result of less probability of tissue coring and/or 
flow to the side of dense dermal tissue. Deeper needle insertion followed by a large 
retraction distance allowed the expansion of compressed dermal tissue and also provided 
a larger void space for injected fluid within the skin thus resulted in increased infusion 
flow rate. Larger infusion pressure induced more tissue disruption thus created a larger 
fluid pathway within dense microstructure of skin. The dispersion of injected solution 
was enhanced by the presence of co-injected hyaluronidase, which temporarily decreased 
skin collagen matrix viscosity. Constant flow rate after elevated flow rate during a brief 
transient was also shown. Altogether, this study shows that microneedles can be 
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fabricated and used in optimized ways to microinfuse therapeutically useful amounts of 
solution into skin with flow rates up to 1 ml/h, which suggests future uses for minimally 
















Building off the results presented in this thesis, I would recommend continuing the 
research effort to exploit the use of hollow microneedles for transdermal drug delivery. 
Hollow microneedles offer additional delivery capabilities beyond diffusion-based solid 
microneedles and allow convective-based injection. Few key issues however remain to be 
answered to effectively use hollow microneedles for microinjection. Fundamental 
understanding of barriers to flow offered by dense dermal tissues is needed to effectively 
use microneedles for injection. Thus, future studies of needle tip optimization and the 
interaction between needle and resistances offered by skin during injection should be 
carried out. The ultimate goal of microneedle research is to build an integrated drug 
delivery device that couples hollow microneedles with a micropump to microinfuse 
therapeutic amounts of drug solutions into skin.  
Fluid delivery through microneedles and into the skin has been demonstrated to be 
strongly dependent on needle tip geometry and tissue resistances. Further refinement of 
needle tip geometry including proper positioning of needle opening (i.e., side opening) is 
crucial to achieve optimal microneedle design to inject into skin and thereby circumvent 
resistances offered by skin tissues such as needle coring, fluid leaking and fluid blocking 
due to rigid skin microstructure. Fundamental understanding of skin anatomy and its 
interaction with the intruding needle has the same importance to allow successful 
injection into skin. Numerical modeling of skin injection using microneedles, which 
emphasizes both needle tip geometry optimization and the presence of rigid skin 
microstructure barriers will serve as a good guidance for further microneedle use as a 
means for fluid delivery. Experimental study which involves detailed real-time imaging 
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(i.e., using fiber optics or x-ray based imaging system) during skin injection and 
microneedle-based infusion would be ideal to complement numerical modeling results to 
provide clear answers to challenges encountered during microneedle injection.  
Combining the mechanistic understanding of infusion parameters on flow rate 
presented in this thesis and the findings of skin-needle interaction during microneedle-
based injection, the next step would be to demonstrate the capabilities of microneedles to 
deliver therapeutic amounts of drugs into living animals and human subjects in a 
controlled fashion when coupled with a micropump. As a short-term in vitro study, a 
further refinement in the control of fluid delivery could be carried out using a constant 
flow rate delivery system (i.e., using syringe pump) based on the constant pressure 
microneedle-based delivery system presented in this study. In addition to protocol that 
involves maximizing retraction distance during infusion described in this thesis, other 
strategies should be pursued to optimize flow rate. One possibility might involve the 
concept of spike-inside-needle device in which an injection can be initiated by inserting 
both a sharp solid spike and a hollow microneedle into the skin, after which the solid 
spike is retracted, after creating an opening for fluid flow into the skin, and the hollow 
microneedle that is still attached to the skin can then act as a delivery channel for fluid 
flow into skin. Rapid insertion of microneedles using high-velocity insertion device could 
potentially minimize skin deflection, thus it can reduce dermal tissue compression and 
resistance to flow. The use of microneedles is envisioned to be in multiple needle arrays 
arrangement, thus, transitioning the results of single glass needle infusion presented in 
this thesis will be necessary to achieve cost-effective and mass-producible microneedle-
based delivery.  
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Preliminary studies shown by others (Smart and Subramanian 2000, Wang, Cornwell, 
et al. 2005) have demonstrated that hollow microneedles could also be used to extract 
fluid. To further demonstrate microneedles capabilities and real clinical applications, 
thus, ultimately, a compact easy-to-use and reliable microneedle-based device could be 
built that has the capabilities to extract interstitial fluid, measure blood glucose levels, 
operate a pump and administer insulin to the body based on blood glucose measurements 












Hollow Side-Opening Microneedles 
 
A.1 Introduction 
As a novel hybrid drug delivery device that captures the benefit of the transdermal 
patch and hypodermic needle, microneedles have been fabricated from different materials 
including silicon (Gardeniers, Luttge, et al. 2003, Henry, McAllister, et al. 1998), metal 
(Davis, Martanto, et al. 2005, Matriano, Cormier, et al. 2002, Mikszta, Sullivan, et al. 
2005) and polymers (Park, Allen, et al. 2005) with different tip geometries. To be useful 
as a minimally invasive drug delivery device, there are three important microneedles 
design constraints: the needle geometry and material must permit insertion into skin 
without breakage, the fabrication method should be inexpensive and easily scaled up, and 
the microneedle must be capable to transport therapeutically effective amounts of drug 
(Davis, Martanto, et al. 2005). Choice of needle materials and needle tip design 
determine needle strength. Needle materials also govern the complexity and cost of the 
fabrication process. Despite its extensive use in microelectronics processes, silicon tends 
to be fragile, is not known to be biocompatible and is relatively expensive (Mikszta, 
Sullivan, et al. 2005, Runyan and Bean 1990). Metals are better materials for microneedle 
fabrication because of their mechanical strength, relatively inexpensive cost and known 
biocompatibility (Braybrook 1997). Polymers have also been used to fabricate 
microneedles (Park, Allen, et al. 2005) since they offer inexpensive and relatively simple 
fabrication process in addition to their biocompatibility and biodegradability (Ratner 
2004), but they are generally not as strong as metals. Various needle tip designs have 
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been demonstrated in previous studies by others including blunt tip (Davis, Martanto, et 
al. 2005), bevel tip (McAllister, Wang, et al. 2003, Park, Allen, et al. 2005) and solid 
sharp tip (Davis, Martanto, et al. 2005) among many other tip designs. To be useful to 
effectively transport drug solution into skin, hollow microneedles must be unobstructed 
during their insertion into skin and during fluid delivery within the skin. 
There are some physical barriers that prevent fluid injection using microneedles into 
the skin. Prevention of fluid flow from the microneedles can be caused by needle tip 
blockage. Tip blockage due to pieces of skin that come inside the needle bore results in 
coring. Needle tip position may also affect the amount of tissue coring. A needle with the 
tip opening at its vertex may result in the higher possibility of coring. On the other hand, 
a sharp-tip needle with side openings may minimize the coring effect. Previous studies 
showed that hollow microtubes were clogged with skin tissue when inserted into skin in 
vitro and in vivo, thus preventing their use to flow fluid into skin (McAllister 2000).  
A separate study of hollow tapered blunt-tip microneedle insertions into rat skin in 
vivo also showed the common occurrence of needle coring by tissue (Davis 2003). An 
observation after the insertion of an array of 16 microneedles with 75 μm tip diameter 
and their removal from the skin indicated that all the needle tips were plugged by 70 μm 
diameter tissue. Similar needles have been shown to not fully insert into the skin (Davis, 
Landis, et al. 2004). As a comparison, sharp solid needles were shown to fully insert into 
the skin (Davis, Martanto, et al. 2005). The extent of the insertion thus was shown to be 
governed by microneedle tip geometry and sharpness. Microneedles with side opening 
holes permit sharper tips, which reduce force of insertion, thus making the device easier 
to use and reducing the need for mechanical strength and/or possibility of needle fracture. 
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All of these led to the growing interest to fabricate microneedles with side openings 
(Gardeniers, Luttge, et al. 2003, Stoeber and Liepmann 2002).   
Building off previous studies, we developed a novel fabrication method to create 
hollow microneedles with side openings with a relatively simple fabrication process 
based on micromolding and laser drilling methods.   
A.2 Materials and Methods 
A.2.1 Micromolding Process 
We used micromolding techniques to make microneedle master structures using the 
tips of metal probes (Picoprobe, GGB Industries, Inc. Naples, FL) with circular 
polycaprolactone base substrate (PCL, 1.14 dl/g, Birmingham Polymers Inc., 
Birmingham, AL). The first step was to define the thickness of the polycaprolactone base 
by inserting the bottom part of a glass vial to a certain depth into a PDMS (Sylgard 184, 
Dow Corning, Midland, MI) mixture, which was heated on a hot plate (250°C). Prior to 
use, air bubbles in the PDMS were removed by applying vacuum pressure of 20 inHg 
(Laboport, KNF Neuberger Inc., Trenton, NJ) for 90 min. After the PDMS was cured, the 
glass vial was removed, which yielded in a PDMS mold with an invagination at the 
center. The tip of a metal probe, held in place by a syringe, was then inserted into the 
invaginated area to a depth that determines the final microneedle height. To make the 
PCL base, PCL pellets were then placed inside the invagination of PDMS mold 
surrounding the metal probe shaft and melted at 250°C. Uniformly-melted PCL was 
shown as solid white materials in the invaginated area of the PDMS mold shown in 
Figure A.1.  
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After the PCL base completely solidified, the PDMS mold was removed to release the 
resulting master structure (shown on Figure A.2), which was then inserted into a liquid 
PDMS that was prepared as above and cured by placing it on a hot plate (40°C) 
overnight. After the PDMS was cured, it was peeled off from the master structure and 
then filled with biocompatible polymer, poly (L-lactic-acid) (LPLA, 1.1 dl/g, 
Birmingham Polymers) pellets and placed inside a vacuum oven (Vacuum Oven 1415M; 
VWR, West Chester, PA). LPLA pellets were melted at 180°C for 30 min. Vacuum 
pressure of 20 inHg was then applied for 1 min to remove entrapped bubbles and ensure 
complete filling of PDMS mold. The vacuum oven was then vented for 5 min. These 
vacuuming and venting steps were repeated a few times to remove all the air bubbles. 
PDMS mold with melted polymer was then kept at 180°C for 30 min before cooling 
down to room temperature. The PDMS mold was then placed in a -20°C refrigerator for 
30 min before releasing the polymer microneedle from the PDMS mold. A representative 





Figure A.1 Schematic of experimental set up to make a microneedle master structure using 




Figure A.2 An image of solid metal probe with polycaprolactone base used as microneedle 
master structure.  
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Figure A.3 An image of solid LPLA microneedle fabricated using micromolding technique. 
 
 
By directly inserting the metal spike without PCL base into liquid PDMS, a 






Figure A.4 An image of solid LPLA microneedle with side skirt fabricated using 
micromolding technique by directly inserting a metal probe into liquid PDMS. 
 
 
A.2.2 Microneedle Fabrication  
To allow electroplating of the insulating polymer mold, a titanium-copper (with 15 
nm and 200 nm thickness respectively) seed layer was deposited on the surface of the 
polymer mold using direct current sputtering (CVC 601). The sputtered mold is shown in 
Figure A.5. Nickel was electroplated onto the sputtered polymer mold to define the wall 
thickness of metal microneedle using a Watts formulation bath (Technic) at room 
temperature and an approximately 10 μm/hr deposition rate for 1 hr. The voltage was 
adjusted to maintain a constant current density of 10 mA/cm2. The duration of plating 
determined the metal microneedle wall thickness. An electroplated mold is shown in 





Figure A.5 An image of copper and titanium sputtered solid LPLA mold. 
 
 
Figure A.6 An image of nickel electroplated solid LPLA mold. 
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To create the side openings, the tip of Nickel-coated polymer mold was then drilled 
using a 248-nm wavelength UV Excimer Laser (Resonetics Micromaster) operated at 80 
Hz and an energy of 180 mJ. Finally, LPLA mold was removed in a methylene chloride 
(Sigma) solution until LPLA was completely dissolved to make hollow metal 
microneedles with side openings. The sequences of laser drilling and electroplating could 
also be reversed in which the side opening holes were drilled after the sputtering step 
rather than after electroplating step. 
A.3 Results and Discussion 
Using a novel microneedle design and fabrication method which combined 
micromolding and laser drilling techniques, we made hollow metal microneedles with 
side openings as shown in Figure A.7 after selectively etching the polymer mold. By 
reversing the fabrication sequences of laser-drilling and electroplating, a similar needle 
fabricated by laser-drilling a sputtered polymer mold and then electroplated the mold is 
shown in Figure A.8. The position of the side-opening hole could be moved to different 
heights along the needle shaft and the size of the hole could be varied by changing laser 
drilling parameters. A similarly fabricated microneedle with smaller side opening holes is 
shown in Figure A.9. Preliminary work demonstrated that side-opening hollow 
microneedles were capable to flow fluid through (data not shown). The fabrication of 
arrays of hollow microneedles with side opening holes could be envisioned using the 
combination of photolithography and laser-drilling techniques to create needle master 
structures and the side opening holes respectively. Although not shown in this study, we 
expect that hollow microneedles with side openings will reduce force of insertion, thus 
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making the device easier to use and reducing the need for mechanical strength and/or 




Figure A.7 An image of hollow metal microneedle with 30 μm side opening holes fabricated 




Figure A.8 An image of hollow metal microneedle with 30 μm side opening holes fabricated 
by laser-drilling a sputtered polymer mold and then electroplated the mold. 
 
 
Figure A.9 An image of hollow metal microneedle with 20 μm side opening holes fabricated 
by laser-drilling a sputtered polymer mold and then electroplated the mold. 
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A.4 Conclusions 
We demonstrated the novel fabrication of hollow microneedles with side openings 
using the combination of polymer micromolding and laser drilling methods. Altogether 
these microneedles have desired properties critical to successful hollow microneedles: 
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